

Review

Exploring the plant-derived bioactive substances as antidiabetic agent: An extensive review



Md. Mominur Rahman^a, Puja Sutro Dhar^a, Sumaia^a, Fazilatunnesa Anika^a, Limon Ahmed^a,
Md. Rezaul Islam^a, Nazneen Ahmeda Sultana^a, Simona Cavalu^b, Ovidiu Pop^{b,*}, Abdur Rauf^{c,*}

^a Department of Pharmacy, Faculty of Allied Health Sciences, Daffodil International University, Dhaka 1207, Bangladesh

^b Faculty of Medicine and Pharmacy, University of Oradea, P-ta 1 Decembrie 10, 410087 Oradea, Romania

^c Department of Chemistry, University of Swabi, Anbar, Swabi, KPK, Pakistan

ARTICLE INFO

Keywords:

Diabetes mellitus
Polyphenolics
Hyperglycemia
Monoterpenes
Flavone

ABSTRACT

Diabetes mellitus (DM) is a metabolic syndrome. Diabetes has become more common in recent years. Chemically generated drugs are used to lessen the effects of DM and its following repercussions due to unpleasant side effects such as weight gain, gastrointestinal issues, and heart failure. On the other hand, medicinal plants could be a good source of anti-diabetic medications. This article aims to determine any plant matrix's positive potential. Food restriction, physical activity, and the use of antidiabetic plant-derived chemicals are all being promoted as effective ways to manage diabetes because they are less expensive and have fewer or no side effects. This review focuses on antidiabetic plants, along with their bioactive constituent, chemically characterization, and plant-based diets for diabetes management. There is minimal scientific data about the mechanism of action of the plant-based product has been found. The purpose of this article is to highlight anti-diabetic plants and plant-derived bioactive compounds that have anti-diabetic properties. It also provides researchers with data that may be used to build future strategies, such as identifying promising bioactive molecules to make diabetes management easier.

1. Introduction

Diabetes mellitus (DM) is defined by serious higher glucose levels occurring due to abnormalities in the production of insulin, or insulin resistance also some individuals can have both reasons [1]. Diabetes affects roughly 29.1 million people each year and is the 7th largest death in the US, obtained to the report CDC [2]. It will be one of the primary causes of mortality in 2030, according to the WHO, with a death rate doubling between 2005 and 2030 [3]. There are two different types of diabetes such as type 1 diabetes mellitus (T1DM) (lack of insulin production) type 2 diabetes mellitus (T2DM) (resistance to insulin activity) and gestational diabetes mellitus is a term used to describe diabetes that develops during pregnancy [4]. T1DM patients make for 5–10% of all diabetics, with type 2 diabetes (Fig. 1) accounting for the rest [5]. On the other hand, the production of insulin is reduced due to the failure of pancreatic-cell (Fig. 2) failure [6]. Gestational diabetes mellitus is defined as "a kind of glucose intolerance that develops in the second and third trimesters of pregnancy, resulting in hyperglycemia of varying

severity" [7]. Characteristics that are shown by diabetic patients like a desire for drinking water, polyuria, blurred eyesight, and weight loss. Ketoacidosis or a non-ketotic hyperosmolality can cause a person to suffer a lack of water in the body and, insufficient treatment can cause mortality [8].

Along with physical activity, a healthy diet is critical for diabetes management [9]. If the treatment is properly administered, all types of oral hypoglycemic medications and insulin are safe in older patients, each medicine has some restrictions related to hypoglycemia risk or co-morbidities [10]. According to Curtis (2007), despite the availability of numerous effective oral hypoglycemic medications 5–10% of case develops secondary failure. Secondary failure occurs when beta-cell activity deteriorates, medication adherence is poor, weight gain, less exercise, dietary changes, or illness occurs [11]. In underdeveloped nations (especially in rural regions), pharmaceutical medications and insulin used to treat diabetes are rare, expensive, and have substantial side effects. Treatment costs are expensive and unaffordable in developing nations, which is a major basic barrier for DM. In light of this,

* Corresponding authors.

E-mail addresses: popo@uoradea.ro (O. Pop), abdurrauf@uoswabi.edu.pk (A. Rauf).

<https://doi.org/10.1016/j.bioph.2022.113217>

Received 14 April 2022; Received in revised form 25 May 2022; Accepted 26 May 2022

Available online 6 June 2022

0753-3322/© 2022 The Authors.

Published by Elsevier Masson SAS. This is an open access article under the CC BY-NC-ND license

(<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

phototherapy and the use of natural items with anti-diabetic properties are often the first lines of treatment and care [12].

Herbal medicine can be a good way to counteract the negative effects of synthetic drugs. Diabetes has traditionally been treated with a variety of medicinal plants [13]. Bioactive compounds are the basic essential component of current medicines, mainly in rural areas, due to their availability, low side effect, and cost-effectiveness [14]. Human pancreatic α -amylase is the digestive system's major enzyme, hydrolyzing starch, glycogen, and different oligosaccharides into smaller oligosaccharides such as maltose, maltotriose, and a variety of - (1-6) and - (1-4) oligoglucans. α -Glucosidase, which is found in the small intestine's brush border, breaks down disaccharides further, making them available for intestinal absorption. The breakdown of dietary starch occurs quickly, resulting in a postprandial spike in blood sugar [15,16]. Inhibition of α -amylases and α -glucosidases is one of the treatment procedures for post-prandial hyperglycemia. Synthetic medications such as acarbose and miglitol block -amylase and -glucosidase, however, they can cause stomach distention, gas, vomiting, and diarrhea [17]. Different types of tannin, flavonoid, catechin, and gallic acids, are identified as antioxidant and hydrolytic enzyme inhibitors α -amylase and α -glucosidases which help to maintain -cell function and lower blood glucose levels [18,19].

One of the main ideas offered to explain the hyperglycemia-induced beginning of diabetic complications is that it is caused by an imbalance between reactive oxygen species capacity and antioxidant defense capability [20]. The production of ROS enhance in all types of diabetic conditions, and diabetic onset is connected to oxidative stress, which is caused by oxidation, no enzymatic protein glycation, and oxidative breakdown of glycated proteins [21]. Because it plays an important part in diabetes etiology, antioxidant treatments may be useful in its therapy [22].

T2DM is becoming more common, with numerous Asian countries ranking in the top ten countries with the greatest number of diabetics [23]. In diabetes therapy, chemical elements taken from plants, called phenolic polyphenols, can reduce amylase absorption [24]. A variety of new compounds from diverse distinct plants have been discovered to have antidiabetic actions [25]. Even though there are over 400 plant species with hypoglycemic action in the literature, researching new antidiabetic medications from natural plants remains appealing as they consist of phytoconstituents that can be used for DM [26]. Thus, the discovery of the best pharmacological component, as well as an effective

therapeutic system for the treatment of this condition [27].

This study aims to discuss the possible active compound of natural plants with anti-diabetic properties which could serve as an alternative to diabetes management.

2. Pancreatic β -cell physiology: insulin biosynthesis

Insulin is made up of 51 amino acids and has a molecular weight of 5.8 kDa. The insulin gene, on the other hand, produces preproinsulin, a 110-amino-acid precursor. Preproinsulin contains a hydrophobic N-terminal signal peptide that interacts with cytosolic ribonucleoprotein signal recognition particles (SRP) [30], as do other secreted proteins. Preproinsulin translocation over the rough endoplasmic reticulum (rER) membrane into the lumen is facilitated by SRP. This happens through the peptide-conducting channel [31,32]. where a signal peptidase cleaves the signal peptide from preproinsulin to produce proinsulin [33]. Proinsulin is next folded and three disulfide bonds are formed [5], a process that requires a variety of endoplasmic reticulum (ER) chaperone proteins, including the protein-thiol reductase [34]. The folded proinsulin is transported from the ER to the Golgi apparatus, where it enters immature secretory vesicles and is broken to release insulin and C-peptide after maturity of the three-dimensional shape. Insulin and C-peptide, as well as islet amyloid polypeptide (IAPP or amylin) and other less abundant β -cell secretory products, are then deposited in these secretory granules [35,36]. Despite the fact that several factors influence insulin production, glucose metabolism is the most critical physiological event that increases insulin gene transcription and mRNA translation [37]. Glucose infusion increased relative proinsulin mRNA levels by three to fourfold within 24 h in 3-day fasting rats, and this effect was prevented by pharmacological transcription inhibition with actinomycin D [38]. These findings imply that glucose plays a key role in insulin biosynthesis regulation, which is influenced at least in part by changes in proinsulin mRNA expression. Furthermore, glucose has a crucial role in the stability of insulin mRNA. Insulin mRNA stability was reduced at lower glucose concentrations and enhanced at higher glucose concentrations, according to in vitro investigations [39,40]. Surprisingly, increasing intracellular cAMP levels prevents this decrease [41]. The insulin gene is only found in a single copy in most species, while rats have two non-allelic insulin genes (insulin I and II). Their number of introns and chromosomal sites varied [42]. The 5'-flanking region of all insulin genes determines tissue and cell type specific expression [43]. In




Fig. 1. Different types of diabetes and their symptoms. The pancreas does not manufacture insulin inside the body in type 1 diabetes, resulting in a weakened immune system. As a result, the person is unable to produce insulin on their own. In type 2 diabetes, the amount of insulin produced by the pancreas is insufficient to maintain the body's glycemic profile. The significant development in Type 2 Diabetes cases at an earlier age, which has overweight children even before puberty, has caused alarm for diabetic people, particularly in developing countries. Insulin is required for type 1 diabetic patients to maintain blood glucose control. Patients with type 2 diabetes can keep their glucose levels under control by eating a healthy diet and exercising regularly [28].

both rat and human insulin genes, transcriptional factor binding sites that determine insulin's exclusive production in β -cells are positioned between -520 and $+1$ base pairs (bp) from the transcription start site (TSS) [37,43,44]. There is a conserved region between -350 bp and the TSS of mammalian insulin genes that affects cell-type-specific insulin production. Interactions within these conserved regions are responsible for the majority of transcriptional control. The stretch between -340 and $+91$ has been identified as the main insulin gene transcription enhancer region [45–50], which determines cell-specific and glucose-regulated insulin gene expression (Fig. 3).

3. Medicinal plants in diabetes prevention

From ancient times in our traditional system, various preparations of plants have been used in the treatment of diabetes mellitus. Further research on finding new plant-derived active compounds could bring a revolutionary change in the pharmaceutical sector or to the existing dietary supplements shortly. Table 1 shows data of some widely available plants which exhibit anti-diabetic properties with their details [52].

4. In-vivo studies in developing antidiabetic agents

Diabetes impacts a variety of metabolic processes in human tissues, many of which can be treated with drugs [84]. Animal models are better suited to assessing medicinal plant's anti-diabetic capabilities in this respect.

Here we have described the detailed in-vivo test information about some of the plants containing anti-diabetic effects;

4.1. *Vernonia amygdalina* Del. (Asteraceae)

Vernonia is the most often used plant in the *Vernonia* genus. *Azadirachta indica* (neems) effects against diabetes were shown by the ethanolic extraction were discovered in an animal. The plasma glucose decreases in an animal in a given extraction mixture and acrid leaves directly differentiate between chlorpropamides and non-diabetic controls. These discoveries supported a previous study that found a low glycemic effect in diabetic animals tested with *Vernonia amygdalina* extraction [85].

4.2. *Hypoxis hemerocallidea* Fisch. (Hypoxidaceae)

Hypoxis hemerocallidea is the most extensively employed in African treatment plants. There are few scientific findings on the anecdotal assertion that *hemerocallidea* has anti-diabetic properties. Streptozotocin was treated with aqueous extraction and the effect on diabetics was shown in diabetic rats which were further evaluated by the investigation of Zibula & Ojewole and Ojewole, who found significant drops in the animals' blood glucose levels [86].

4.3. *Gymnema sylvestre* (Apocynaceae)

Gymnema sylvestre (Asclepiadaceae) is a woody climber identified in India's central and southern tropical forests. By rebuilding pancreatic islets and beta cells in diabetic rats, a water-soluble extract of *Gymnema sylvestre* leaves lowered blood glucose levels. The glycogen level of the tissue in glucose-fed rats was reduced by an aqueous dissolved fraction of alcohol extraction of *Gymnema sylvestre* leaves, but it was not affected in normal rats [87]. In T2DM, a daily dose containing 400 mg water-soluble extract of *Gymnema sylvestre* significantly reduced insulin demands while also lowering HbA1c levels [88].

5. In-vitro evaluation of antidiabetic agents

One of the most common methods for managing blood sugar levels is to inhibit critical enzymes. *Abelmoschus moschatus*, *Alangium salvifolium*, *Boerhaavia diffusa*, *Capsicum frutescens*, *Mangifera indica*, *Momordica charantia*, *Ocimum sanctum*, *Punica granatum*, and *Zingiber officinale* have all shown enzymes inhibition effect with potential benefits on diabetes and hyperglycemia [89].

5.1. In vitro studies on glucose uptake

In HIT-T15 Hamster pancreatic β -cells, an aqueous extract of *Momordica charantia* demonstrated strong cell mending actions and the promotion of insulin secretion [90]. *Pterocarpus marsupium* methanol extracts exhibited glucose transportation activity in the PPAR α mediated PI3 kinases dependent manner, while *Pterocarpus marsupium* isoflavone showed glucose transportation effect in a PPAR α mediated but PI3 kinase-independent manner [91].




Fig. 2. Representation of pancreatic cells and the release of insulin. Pancreatic endocrine tissue is organized as clusters of cells dispersed throughout the exocrine pancreas and makes up less than 1% of the pancreas. The islets of Langerhans are heterogeneous cell clusters made up of three main cell types that release different hormones. The bulk of islet cells is insulin-secreting cells that also serve as glucose sensors, releasing insulin in response to elevated blood glucose levels. The right panel depicts the process that regulates insulin production from β cells [29].




Fig. 3. Glucose-induced insulin secretion pathways. Glucose enters the beta cell quickly via specialized glucotransporters and is phosphorylated by glucokinase, which controls metabolic flux via glycolysis. The tricarboxylic acid cycle produces reducing equivalents once pyruvate enters the mitochondria. After then, ATP is produced, and the increased ATP/ADP ratio induces the ATP-sensitive K⁺ (KATP) channels in the membrane to close. The influx of extracellular Ca²⁺ and activation of exocytosis are caused by sequential depolarization of the plasma membrane. Insulin may be affected by other chemicals produced in the mitochondria [51].

5.2. *In vitro* studies using α -amylase inhibition assay

α -amylase is an enzyme that breaks down starch into simpler sugars and is essential in the human body. Decomposition of carbohydrates may help persons with diabetes manage their insulin resistance and glycemic index [92]. Citrus *macroptera* Montr. Methanol extract had an IC₅₀ of (3.6380.190) mg/mL, whilst normal acarbose had an IC₅₀ of (0.9120.015) mg/mL. Methanol extract, like acarbose, strongly reduced α -amylase activity in a dose-dependent manner. As a result, *C. macroptera* extract has a mild anti-amylase activity [93]. *Andrographis paniculata* ethanolic extract inhibited α -glucosidase activity in a concentration-dependent mode. It also had a mild inhibitory effect on α -amylase. *Andrographis paniculata* was addressed as a promising choice to treat T2DM, according to the findings [94].

5.3. *In vitro* studies using insulin-secreting cell lines

The presence of insulin secretagogue in *Tinospora cripa* extract caused a rise in cytosolic Ca²⁺ uptake from the extracellular medium while suppressing Ca²⁺ efflux from the cytosol, resulting in insulinotropic action in HIT-T15 cells. HIT-T15, MIN6, AND RINm5F are a few examples. Insulin secretion is triggered by permeabilization of the beta-cell plasma membrane and channel-independent Ca²⁺ influx into the beta-cells. Aqueous extract of *Viscum album* (mistletoe) increase secretion in clonal BRIN-BD11 pancreatic beta-cell in a dose-dependent manner [95].

6. Importance of herbs in diabetic management

Diabetes mellitus is a serious metabolic illness, and medicinal herbs play an important part in its therapy. Traditional plants have been shown to offer potent anti-diabetic capabilities with no negative side effects [96]. According to studies, traditional plants are used as the first-line treatment for eighty percent of people in underdeveloped countries. In many poor nations, traditional medicines play an essential role in primary health care [97].

Herbal medicine is now frequently utilized to treat diabetes due to the lower cost and easier accessibility of medicinal plants over conventional drugs. With low adverse effects, this therapeutic alternative can be utilized as an anti-diabetic treatment when combined with other anti-diabetic medications or insulin [98]. Clinicians should employ herbal medications to treat DM and associated complications, according to the World Health Organization. Apart from their hypoglycemic

activity, research has shown that a variety of antidiabetic plants have other helpful qualities such as antihypertensive, nephroprotective, and retinoprotective activities, which may be useful against the most prevalent complications of diabetes. As a result, eating these plants could be beneficial in the treatment of diabetes and its consequences [99].

7. Natural products for the prevention of insulin resistance in diabetic conditions

Type 2 diabetes mellitus occurs in 90% of individuals, with insulin resistance (IR) being the primary pathophysiological sign. In adipose cells and skeletal muscle cells, IR was mostly attributed to the malfunction of glucose. IR is mainly ascribed to the dysfunction of glucose transporter 4 (GLUT4) moving from the cytoplasm to the membrane, which was linked to an aberrant insulin signaling pathway [100]. Adipose tissue has been proven in numerous studies to aid maintain glucose homeostasis by boosting glucose absorption in skeletal muscle and lowering glucose production in the liver. As a result of insulin resistance, the incretin action is reduced, glycogenesis is reduced, and pro-inflammatory proteins and cytokines are produced in greater quantities (Fig. 4). After the insulin combines with its receptor, the downstream signal transduction is mainly controlled by insulin receptor substrate-R-as-mitogen-activated protein kinase (IRS-RaS-MAPK) and IRS-1-phosphoinositide-3-kinase-protein kinase B (PKB, known as Akt) IRS-1-PI3K-Ak [101–103]. The former plays a significant role in various biological processes—glycogen synthesis, metabolism, glucose transport, and utilization, which are indispensable in the occurrence and development of IR, while the latter regulates the growth and apoptosis of cells [104–106].

Medicinal substances can be used to convert resistance to sensitivity in cells [107]. *Urtica dioica* leaves extraction by hydro alcohol substance layout a low glucose action in male wistar rat by fructose generated resistance of insulin. Two weeks later different intraperitoneal administration of *Urtica dioica* extraction dosages, the examined animal displayed a significantly low level of plasma glucose count & fasting insulin resistance index and the effect were dose-dependent. Furthermore, the treatment group's serum insulin concentration was much lower than the control group's, indicating that the usage of leaf extract boosted tissue and cell sensitivity, as indicated by the lower plasma glucose level [108].

In STZ-induced neonatal diabetic animals, an *Anacardium occidentale* leaves ethanolic extraction has anti-diabetic properties. Fasting glucose count of insulin in serum was (11.60 0.89 IU.mL⁻¹), and Fasting insulin

Table 1
Medicinal plants in diabetes prevention with respective mechanisms and clinical interventions.

Scientific Name	Family	Place of Study	Used Parts	Preparation	Active Ingredient	Mechanism of Action	Route	Dose	Type of Study	Ref.
<i>Acalypha godseffiana</i>	Euphorbiaceae	Nigeria	Leaves	Acetone, Aqueous, Ethanol and Methanol extract.	Flavonoids; Proanthocyanidins	Inhibits the α -glucosidase enzyme.	Oral	1.38 mg/mL	in vitro	[53]
<i>Allium sativum</i> L.	Amaryllidaceae	–	Bulb	Crushing or Cutting	Allicin	Anti-hyperglycemic	Oral	0.5 mg/mL	in vivo	[54]
<i>Aloe barbadensis</i>	Asphodelaceae	Mexico	Leaves	Methanolic extract	Polysaccharides	Inhibited the α -amylase and α -glucosidase enzyme.	Oral	5 mg/mL	in vitro	[55]
<i>Amaranthus hybridus</i> L.	Amaranthaceae	India	Leaves	Ethanol extract	Flavonoids, glycosides, terpenoids, saponins, alkaloids, tannins, and steroids.	Reduces the level of high glucose in the blood.	Oral	200 and 400 mg/kg	in vivo	[56]
<i>Angiopteris helferiana</i>	Marattiaceae	Nepal	Rhizome	Aqueous extract.	Lactones	Inhibited the enzyme α -glucosidase	Oral	150 mg/kg/day and 300 mg/kg/day	in vivo	[57]
<i>Areca catechu</i>	Areaceae	Indoneisa	Seed	Ethanol extract.	Pyridine and piperidine alkaloids	Positive glucose tolerance test.	Oral	22.5 mg; 45 mg and 180 mg per 200gr body weight	in vivo	[58]
<i>Azadirachta indica</i>	Meliaceae	Kenya	Leaf	Aqueous extract.	Flavonoids; Tannins; Sterols; Saponins, Anthraquinones; Alkaloids	Hypoglycemic	IntraperIntraperitoneall.	25 mg/kg, 48.4 mg/kg, 93.5 mg/kgb, 180.9 mg/kg and 350 mg/kgbwt	in vivo	[59]
<i>Barringtonia acutangular</i> (L.)	Lecythidaceae	–	Bark and seed	Aqueous extract	Triterpene saponins	Anti-hyperglycemic	Oral	–	in vivo	[60]
<i>Barleria prionitis</i>	Acanthaceae	India	Leaf and root	Alcoholic extract.	Further studies are required.	Hypoglycemic	Oral	200 mg/kg	in vivo	[61]
<i>Bauhinia holophylla</i>	Fabaceae Lindl.	Brazil	Leaves	Aqueous extract	Kaempferitrin	Reduces body weight.	Oral	400 mg/kg	in vivo	[62]
<i>Benincasa hispida</i>	Cucurbitaceae	Japan	Stem	Chloroform extract.	Volatile oils; Flavonoids; Glycosides.	Anti-hyperglycemic	Oral	250 mg/kg and 500 mg/kg	in vivo	[63]
<i>Carica papaya</i>	Caricaceae	Nigeria	Leaves	Ethanol extract.	Flavonoids; Alkaloids; Glycoside; Phenols.	Hypoglycemic	Oral	200 mg/kg, 400 mg/kg and 600 mg/Kg	in vivo	[64]
<i>Carthamus tinctorius</i>	Asteraceae	Pakistan	Flower	Ethanol extract	Neocarthamin; Cathamidin; Carthanin; Lignans and Polysaccharides.	Anti-hyperglycemic	Oral	200 mg/kg and 300 mg/kg	in vivo	[65]
<i>Coccinia grandis</i>	Cucurbitaceae	Bangladesh	Leaves	Ethanol extract.	–	Reduced body weight Anti-hyperglycemic	Oral	750 mg/kg	in vivo	[66]
<i>Coriandrum sativum</i>	Apiaceae	Thailand	Seeds	Ethanol extract	Linalool	Hypoglycemic Increased pancreatic β -cells activity Increases release of insulin.	Intraperitoneal	200 mg/kg and 250 mg/kg	in vivo	[67]
<i>Cuminum cyminum</i>	Apiaceae	Egypt	Seeds	Ethanol extract	Phenols; Flavonoids.	Anti-hyperglycemic Increased insulin sensitivity.	Oral	200 mg/kg	in vitro	[68]
<i>Diospyros peregrina</i>	Ebenaceae	India	Fruit	Aqueous extract	–	Hypoglycemic	Oral	50 mg/kg and 100 mg/kg	in vivo	[69]
<i>Elaeocarpus grandiflorus</i>	Elaeocarpaceae	Thailand	Leaves; Twigs; Fruits	Aqueous extract.	Further studies are required.	Hypoglycemic	Oral	0.0001, 0.001 or 0.01 g/kg	in vivo	[70]
<i>Emblica officinalis</i>	Phyllanthaceae	Pakistan	Fruit	Methanolic extract.	Ellagic acid	Decreased fasting glucose in blood	Oral	250 or 500 mg/kg	in vivo	[71]

(continued on next page)

Table 1 (continued)

Scientific Name	Family	Place of Study	Used Parts	Preparation	Active Ingredient	Mechanism of Action	Route	Dose	Type of Study	Ref.
<i>Ficus Recemosa L.</i>	Moraceae	India	Unripped fruit	Ethanol extract	Bioflavonoids; Glycosides; Alkaloids;	Increased insulin in serum. Hypoglycemic	Oral	400 mg/kg	in vivo	[72]
<i>Fraxinus ornus</i>	Oleaceae	Egypt	Leaves	Hydroethanolic extracts	Tannins; Flavonoids; Saponins; Alkaloids.	Anti-hyperglycemic	Oral	10 mg/kg and 50 mg/kg	in vivo	[73]
<i>Gynura procumbens</i>	Asteraceae	Malaysia	Leaves	Aqueous extract.	Kaempferol-3-O-rutinoside; Astragalin.	Decreased fasting glucose in blood	Intraperitoneal	500 mg/kg or 1000 mg/kg	in vivo	[74]
<i>Hibiscus sabdariffa</i>	Malvaceae	Nigeria	Leaves	Aqueous extract.	Flavonoids;	Anti-hyperglycemic.	Orally	200 mg/kg, 400 mg/kg and 600 mg/kg	in vivo	[75]
<i>Ilex paraguariensis</i>	Aquifoliaceae	Uruguay	Leaves and stems	Aqueous extract	Theobromine; Chlorogenic Acid; Caffeic acid; Caffeine.	Anti-hyperglycemic; Anti-oxidant.	Oral	580 mg/kg	in vivo	[76]
<i>Jatropha curcas</i>	Euphorbiaceae	Nigeria	Leaves	n-Hexane extract	–	Hypoglycemic; Reversed Increased level of nitric oxide.	Oral	200 mg/kg	in vivo	[77]
<i>Lavandula stoechas L.</i>	Lamiaceae	Tunisia	Flower	Boiling; Distillation (Essential Oil)	Linalool	Hypoglycemic	Intraperitoneal	50 mg/kg	in vivo	[78]
<i>Leucas aspera (Willd)</i>	Lamiaceae	India	Leaf and stem	Ethyl acetate, Acetone and Hydro alcoholic extracts	Flavonoids; Polyphenols; Tannins; Alkaloids; Glycoside; Saponins; Phytosterols and Triterpenoids	Inhibition of glycosylation.	oral	10 µg/mL	in vitro	[79]
<i>Mangifera indica L.</i>	Anacardiaceae	Vietnam	Leaves	Ethanol extraction	Mangiferin	Inhibited the enzyme α -amylase	oral	200 µg/mL	in vitro	[80]
<i>Melissa officinalis</i>	Lamiaceae	South Korea	Leaves	Aqueous extract	Monoterpene hydrocarbons; Oxygenated monoterpenes; Sesquiterpene hydrocarbons	Anti-hyperglycemic. Showed an improvement in glucose tolerance.	Oral	250 mg/kg	in vivo	[81]
<i>Mentha × piperita L.</i>	Lamiaceae	India	Leaves	SA-elicited peppermint infusion	–	Hypoglycemic. Reduced urine, urine urea, uric acid and microalbumin.	oral	100 g/L	in vitro	[82]
<i>Tagetes erecta L.</i>	Asteraceae	China	Inflorescence	Ethanol extraction	Rutin; Quercetin; Quercetagenin	Inhibited the α -amylase and α -glucosidase enzyme	oral	250 mg/kg	in vitro	[83]




Fig. 4. Mechanism of action of insulin resistance in the human body.

resistance index levels were significantly reduced after oral application of 99.99 mg/kg weight in *Anacardium occidentale* extraction in one month [109].

Symplocos cochinchinesis bark ethanolic extraction has been demonstrated to show insulin resistance inhibition properties. On day 20, diabetic caused rats with insulin resistance received by an oral dose of *Symplocos cochinchinesis* extraction of two hundred and fifty and five hundred mg kg⁻¹.day⁻¹ [110]. Concurrently, it was found that in the treatment group, plasma insulin levels and the HOM-IR were significantly reduced than in the group, implying better cell susceptibility to endogenous insulin [110].

7.1. Terpenoids

Protopanaxatriol is a novel antagonist of peroxisome proliferator-activated receptor- γ (PPAR γ), which regulates metabolic and inflammatory gene expression such as interleukin, interleukin-10 (IL-10), interferon- γ (IFN- γ), inducible nitric oxide synthase (iNOS) and CD68 improving insulin sensitivity, dyslipidemia, and steatosis [111]. Cucurbitacin B is a kind of tetracyclic triterpenoid isolated from *Trichosanthes dioica*. Cucurbitacin B improved insulin tolerance and glucose utilization through translocation of GLUT4, which was related to the activation of the PI3K/Akt signaling pathway [112]. Guavenoic acid (0.3–30 nmol/L) could significantly improve the insulin resistance of INS-1 cells, which was related to the down-regulation of protein tyrosine phosphatase 1B (PTP1B) gene expression and up-regulation of PPAR gene expression [113]. Deoxyandrographolide is mainly derived from the *Andrographis paniculata*, which concentration-dependently induced glucose uptake by increasing the translocation of GLUT4 on the cell surface and activating PI3K and AMPK dependent signaling pathway [114]. Ginsenoside Rb1 induced translocation of GLUT4 by upregulation of leptin receptors and activation of PI3K, which improved insulin sensitivity and glucose metabolism in skeletal muscle cells [115,116].

7.2. Alkaloids

Berberine is an isoquinoline alkaloid isolated from *Coptidis rhizoma* or *CortePhellodendronri*, two Chinese herbs. Berberine may improve glucose tolerance by influencing critical molecules such as AMPK and PKC (paroxysmal kinesigenic choreoathetosis) in the insulin signaling pathway, as well as AS160 phosphorylation and GLUT4 translocation, resulting in increased glucose uptake in insulin-resistant cell. Mahanine has been reported to be a major bioactive carbazole alkaloid. Mahanine (5–10 mol/L) could improve glucose metabolism in L6 myotubes and adipocyte cells via modulation of the Akt signaling pathway and then raised plasma membrane GLUT4 content [117]. Capsaicin is a pungent principal compound of hot chili peppers. It was demonstrated that

promoted glucose utilization in C2C12 muscle cells by modulating AMPK, ROS (reactive oxygen species), and the p38 MAPK signaling pathway [118,119].

8. Advantages of plant-based bioactive compounds

Phenolics and carotenoids are two essential bioactive molecules that can help to keep improve human health. Food comprises a wide range of nutritional components which are required to survive, also several substances with bioactive quality that aid in the improvement of health and illness prevention. Secondary metabolites aren't required for a plant's overall growth or functioning, but they often contain therapeutic properties that make them useful in the treatment of diabetes. Natural food components contain Mg, Ca, and K including phytochemical, dietary fibers, carotenoids, and vitamins.

The current treatment for diabetes mellitus (DM) focuses on maintaining and reducing plasma glucose count within normal levels [120]. Nowadays 6 basic types of contemporary medications, and also two classes of injections, are being used to regulate blood glucose levels all around the world. Biguanides, sulfonylureas, thiazolidinediones, alpha-glucosidase inhibitors, and DPP-4 inhibitors are all names for the tablets. Incretin mimetics and insulin are two types of injectable drugs [121–124]. As of now, different techniques for managing DM, such as diet restriction, physical activity, and plant-derived molecules such as antidiabetics are recommended because they are less expensive and have fewer or no adverse effects [125]. According to the World Health Organization, roughly 75–80% of the global total, mostly in developing nations with diverse plant life, still rely on a plant-based traditional medical system. Conventional drugs are generally the 1st option to use in health lines in impoverished states as they're more culturally acceptable, and more suitable due to fewer adverse effects compared to contemporary treatments. Certain medicinal plants have lately been discovered to be effective in the treatment of diabetes, and they have been utilized as antidiabetic medicines all around the world. There are over 400 plant species that exhibit hypoglycemic action [126]. Previous studies have discovered a connection between the consumption of a particular herbal product and the development of diabetes, also diet plans help to maintain a good life. Fruit, vegetable consumption [127], and whole grains are inversely related to the development of diabetes [128,129].

9. Natural antidiabetic bioactive compound's mechanism of action

Diabetes is an oxidative stress-related disease characterized by a mismatch between the reactive oxygen species (ROS) generation in cells. The substances that are obtained from the live organism are known as natural compounds. Plants are principal suppliers of natural chemicals. Secondary metabolites are a wide category of natural substances that plants create. Phytoconstituents & active compounds derived from them could be effective treatments for diabetes and serious comorbidities with very few negative impacts. Anti-diabetic characteristics have indeed previously been identified in a wide range of effective medicinal herbs and their endogenous bioactive components, and they are presently more of it in need over manufactured drugs for the treatment of hyperglycemia due to their wide accessibility, potency, and lack of adverse effects (Table 2) [130].

Apigenin is a natural flavonoid [132]. that decrease IL-6, IL-1, and TNF through the alteration of the various intracellular signaling pathway of macrophage, reducing hyperglycemia and increasing antioxidants through oxidative stress-related anti-inflammatory options.

Hesperidin is a glycoside [133]. that reduces the symptoms of diabetes by lowering the release of all pro-inflammatory cytokines by controlling hyperglycemia and hyperlipidemia levels. Hesperidin reduces oxidative stress and increases insulin resistance by having a high antioxidant capacity and associated enzymes [134].




Fig. 5. 3D representation of the docking position of β -orbital with human glucose transporter (PDB 4PYP).




Fig. 6. Crystal structure of glucose-fructose-6 phosphate aminotransferase (PDB2ZJ3).

phenolic compounds present in the fruit includes gallic acid, protocatechuic acid, ellagic acid, ferulic acid, caffeic acid, p-coumaric acid, and chlorogenic acid. These are potent antioxidants with considerable anti-diabetic properties. These could be able to successfully improve carbohydrate absorption & gluconeogenesis, hence alleviating diabetes glucose levels & consequences [138–141]. Phenolic-rich litchi or lychee pulp preparations protect the pancreatic cell [142]. In STZ-induced diabetic animals oxidative stress, apoptosis, and diabetes-induced hepatic damage in animal were also studied [143].

12. Bioactive compound's biomarker discovery for the development of antidiabetic drug

A biomarker is a trait that may be measured and assessed objectively as a sign of normal biologic activities, pathogenic processes, or pharmacologic reactions to a therapeutic intervention". Biomarkers have significant economic and medical potential are appropriate monitoring utilizing biomarkers could reduce medication attrition throughout clinical phases as well as overall development expenses. In insulin resistance and diabetes conditions, metabolic investigations have revealed previously unknown alterations in metabolic pathways. The relationship between improper metabolism of amino acids and resistance of insulin is one of the most significant of these discoveries. Branched-chain amino acids and branched-chain keto acids are shown to be higher in the blood of diabetic patients [144].

Metabolite profiling has found significant variations between diabetes and non-diabetic individuals also alanine, formic acid, and trigonelline, betaine among other urine metabolites. Investigating the metabolic pathways that involve these metabolites could yield new insights into the pathophysiology of diabetes and how these metabolites play a role. Other diabetes-related biomarkers discovered recently include phosphatidylcholines, 2-hydroxyethanesulfonate methyl succinate, guanidinoacetate, methyl guanidine, and hippurate. The retinoid family of phytochemicals includes the phytochemicals boeravinone E and boeravinone D, which are plentiful in *Boerhaavia diffusa* and have significant medicinal promise. The phytochemicals boeravinone E and boeravinone D, which are abundant in *Boerhaavia diffusa* and have great therapeutic potential, belong to the retinoid family of

phytochemicals. Both compounds were discovered to be deeply lodged in the active pocket and to interact with Glu63 in the surrounding region, allowing new anti-diabetic drug development. *Annona glabra* contains a lot of squamosamide, and a derivative of it is quite effective against diabetes. It protects pancreatic β -cells from glucose toxicity by increasing the Akt-FOXO1 pathway, which has substantial hypoglycemic and anti-inflammatory effects [145].

13. Functional food management for a diabetic and pre-diabetic condition

Pre-diabetes is a state in which blood glucose concentration is above baseline but maybe not excessive enough to be confirmed as diabetes [146]. Pre-diabetes condition is a serious risk factor for diabetes that is characterized by moderate hyperglycemia [147]. Diabetes is unavoidable for persons with pre-diabetes, the chance of developing diabetes can be minimized by implementing early action [148].

According to the International Diabetes Federation, there will be 471 million people globally with pre-diabetes in 2035 [146]. One of the most important features of a functional food supply is that it is high in nutritional content and low in calories, both are beneficial to human health. Increase Easy availability of foods that are high in preventive nutrients is also beneficial in treating illnesses. Functional food security in combination with increased moderate exercise, which is an effective weight loss technique, may be the key to considerable success in the treatment of obesity and type 2 diabetes. It is widely recognized that Mediterranean-style dietary patterns include excessive intake of functional foods (vegetables, legumes, whole grains, fruits, nuts, and olive oil), moderate consumption of fish and wine, and low consumption of red and processed meat, as well as whole-fat dairy products; this is widely recognized as a healthy dietary pattern, rich in functional foods, and similar to the Paleolithic diet; this is widely recognized as a healthy dietary pattern, rich in functional foods, and similar to the Pale [149–153].

13.1. Quinoa seeds

Quinoa seeds (*Chenopodium quinoa*) are widely grown in South

America. They have a high nutritional profile and are resistant to climate change, making them a crucial seed for the future food sector [154]. The Bolivian culture called it 'jupha,' or 'quinia.' Near 5000 years ago, the species was domesticated in the South American range zone around Titicaca Lake. It now stretches to the north and south of the continent along with a mountain range, from Colombia to Chile's south, where it can be found growing wild or cultivated [155]. It is said to assist high-risk patient groups, such as those with diabetes, dyslipidemia, and obesity, due to its high nutritional content, therapeutic properties, and gluten-free status. Minerals, fibers, vitamins, fatty acids, antioxidants, and phenolic, all of which have a substantial impact on human nutrition and well-being, are closely linked to the levels of minerals, fibers, vitamins, antioxidants, and phenolic in its seeds [156]. Quinoa consumption decreased blood glucose and insulin resistance in test subjects, implying that it had a substantial role in diabetic treatment [157].

13.2. Chia seeds

Chia (*Salvia hispanica* L.) seeds are an annual herbaceous plant that can be found in Northern Guatemala and Southern Mexico. Its name stems from the Latin word "salvere," which refers to the medicinal and culinary characteristics of the well-known *Salvia officinalis* herb, often known as Mexican chia or Salba chia [158]. As a Vita food, chia seeds play a prime role. The content and concentration of its bioactive components are affected by circumstances such as climate, geographical origin, and extraction processes. Chia seeds are high in -linolenic acid (ALA), a fatty acid that reduces the resistance of insulin in T2DM and its complications. It also helped to treat diabetes by lowering serum glucose, cholesterol, and triglycerides levels, and postponing the onset of diabetes in borderline test subjects [159]. Chia seeds have recently been designated the finest source of fatty acids. They're also abundant in bioactive substances including phenolic compounds and tocopherols, both of which have anti-diabetic properties [160].

13.3. Hab El-Rashad seeds

Hab El-Rashad seeds, also known as *Lepidium sativum* Lare an edible plant that belongs to the cruciferous plant family. This species was used as a grain in ancient Greece. Long before the advent of bread, *L. sativum* was a nutritional source for ancient Egyptians, who utilized it as a staple diet Hab El-Rashad is the Arabic name for *L. sativum*, which is widely used in Egypt and Saudi Arabia. Hab ElRashad seed powder and alcoholic extracts demonstrated a cytoprotective impact in pancreatic islets in a high-fat diet rodent model, maintaining the integrity of the cell that controls appropriate insulin secretion and maintaining glucose levels to normal in test subjects, according to recent studies [161]. the extraction of Hab ElRashad seeds stabilizes diabetes by enlarging antioxidant activity, decreasing oxidative stress, and improving lipid profile, as well as regulating insulin pancreatic secretion from pancreatic islet cells, which is linked to lower glucose, urea, triglycerides, and cholesterol levels [162].

13.4. Pumpkin seeds

Pumpkin seeds (*Cucurbita pepo* L.) are high in phytosterols, proteins, vitamins, and minerals, they are widely utilized in edible seeds all over the world [163]. According to recent studies, pumpkin seeds have piqued the interest of the food sector, which is looking for healthier alternatives. Proteins, crude fibers, calcium, carotene, and vitamin C were discovered to have a high nutritional profile in the seeds, which aid in weight loss. It was claimed that the ingestion of natural bioactive substances with a documented anti-obesity activity has gained special attention in scientific circles because of its capacity to control weight growth and aid in weight loss [164]. Pumpkin seeds have anti-diabetic properties, thanks to their hypoglycemic and hypolipidemic properties. According to current research, diabetic rats' cellular insulin

absorption was boosted, indicating that the cells' ability to use insulin and glucose was greatly increased. It was also discovered that alcoholic extracts of pumpkin seeds could block -amylase, while aqueous extracts exhibited considerable inhibition of amylase and -glucosidase, both of which are directly linked to the antidiabetic action that has lately been considered for pumpkin seeds [165].

13.5. Fenugreek seeds

Fenugreek seeds are a yearly bean crop farmed primarily for use as a spice in many regions of the world. The plant is a scented herbaceous annual that is extensively grown in Mediterranean and Asian nations [166]. Recent pharmacological research has revealed that fenugreek includes several active compounds that modulate glycolipid metabolism and improve insulin resistance. In addition, 4-hydroxy isoleucine was discovered to have a significant impact on lowering insulin resistance, which aids in the reduction of obesity in test individuals. However, the exact mechanism is unknown, and more research into this seed's anti-obesity properties is needed [167]. Alkaloids, essential oils, proteins, steroidal saponins, mucilaginous soluble fiber, and insoluble fibers) are present in fenugreek seeds and are responsible for their biological activity. In test individuals, these ingredients aid in lowering serum glucose levels and inflammatory mediators that cause mild inflammation which is one of the main reasons for obesity and insulin resistance. As a result, the fenugreek seed is a promising anti-obesity candidate. Phytomedicine [168–172]. A range of elements in fenugreek seeds, including galactomannan, phenolic compounds, and fibers, have been discovered to have hypoglycemic effects. Clinical investigations have indicated that 2–3 g of fenugreek gum per day is beneficial in managing blood sugar levels, although other food fiber requirements are substantially higher (up to 20 g). The fenugreek gum thickens and creates a gel in the stomach, trapping sugars, lipids, and starch-hydrolyzing amylase enzymes, resulting in a slowdown of sugar absorption, which is beneficial to diabetic and obese people [145, 173–178].

14. Wild edible plants in diabetes management

14.1. *Artemisia annua* L. Leaves

In vitro, the caffeoylquinic acid derivatives inhibited the activity of the DPP-IV, -amylase, and -glucosidase enzymes. These effects may account for *Artemisia annua*'s well-known antidiabetic activity by the enhancement of insulin release, preserving pancreatic -cells, delaying glucose absorption and lowering postprandial glucose excursion. Surprisingly, some of these substances aided wound healing [179].

14.2. *Brassica juncea*

B. juncea (Cruciferae). *B. juncea* has been ingested in all countries. The parts that are used include leaves and seeds. Its various parts can be utilized to make vegetables and seeds can be used as a condiment or a source of oil. These components contain glucosinolates, isothiocyanates, phenolics, Kaempferol, glycosides, and flavonoids [180]. In STZ-induced diabetic rats, aqueous seed extract resulted in a remarkable reduction of blood glucose levels and a rise in serum insulin in a dose-dependent way [181].

14.3. *Nigella sativa* (*N. sativa*; *Ranunculaceae*)

Nigella sativa is primarily grown in the Middle East and Southwest Asia. Powder, extract, and seed oil were all used. Thymoquinone (the major component), flavonoids, unsaturated fatty acids, nigellone, p-cymene, and carvone are some of the compounds found in thymoquinone [107,182]. *N. Sativa*'s action mechanism has been demonstrated in human and animal research to include effects on antioxidants, enzymes,

insulin secretion, glucose absorption, gluconeogenesis, beta-cell function, and gene expression [182–186].

15. Plant-based nanoparticles in diabetes management

15.1. Ginger nanomaterials

High-fat diet-fed mice were given ginger-derived nanoparticles (GDNP) in their drinking water for at least one year or the rest of their lives. The gene expression profile of GDNP-treated mice was analyzed using a microarray profile of their intestine, liver, and fat tissue. The interaction between the Foxa2 protein and phosphatic acid-lipid nanoparticles was studied using surface plasmon resonance (SPR). Obesity has spread over the world for overconsumption of high-fat diets (HFD), which is the main reason for major chronic diseases like type 2 diabetes. Dietary management is the cornerstone of obesity and diabetes prevention. However, the molecular mechanisms of diet-based prevention of insulin resistance are still unknown. Treatment with GDNP reduces the resistance of insulin in rats fed a high-fat diet by restoring balance in gut epithelium Foxa2 mediated signaling (HFD). By protecting Foxa2 from Akt-1-mediated phosphorylation, GDNP therapy can prevent HFD-induced obesity and insulin resistance [5,187,188].

15.2. Curcumin nanomaterials

Diabetes is a complex metabolic condition that necessitates lifelong pharmacological therapy as well as lifestyle adjustments. Curcumin is one of the most researched bioactive components in traditional medicine, although it has poor solubility, absorption, and activity due to its physicochemical properties. Curcumin's low bioavailability can be overcome by nanotechnology-based pharmaceutical formulations, which can boost its anti-diabetic properties. Nanocurcumin's anti-diabetic properties are attributable to multiple pharmacological pathways that reduce DM's hallmark hyperglycemia. Nanocurcumin may be considered a possible drug in the pharmacotherapeutic management of diabetic patients in light of these findings [189–191].

15.3. Selenium nanoparticles

The principal aspect of the diabetes treatment and management process is the lowering of hyperglycemia following carbohydrate consumption, which can be accomplished by inhibiting alpha-amylase. Diabetic rats were given the extract that produced the best outcomes in vivo trials. In a diabetic rat trial, the brewed extract had a substantial effect on fasting glucose reduction and a non-significant effect on triglyceride, cholesterol, and LDL decrease [192].

Some data from human studies and medicinal plants in the management of type 2 diabetes mellitus in ASEAN countries are shown in Table 3.

16. Plants having an anti-diabetic effect

16.1. Albizzia lebeck (Fabaceae)

Streptozotocin-induced diabetic rats received a different dose of a methanol/ extract from *Albizzia lebeck* stem bark for 30 days [194]. The therapy reduced fasting blood glucose and glycated hemoglobin while increasing plasma insulin. It also reduced TC, triglyceride low-density lipoprotein, and VLDL LDL while increasing high-density lipoprotein. In streptozotocin-induced diabetic rats, the therapy increased and reduced glutathione peroxidase, CAT, glutathione, and SOD levels while decreasing lipid peroxidation. The therapy also protected the liver, pancreas, liver, and heart of the diabetic rats and reduced lesions in a dose-dependent way. *Albizzia lebeck* bark methanolic extract has toxicological effects on diabetic rats caused by streptozotocin and nicotineamide [195].

Table 3

Completed summary of data extraction of selected published literature articles on human studies and medicinal plants in the management of type 2 diabetes mellitus in ASEAN countries [193].

Plant name and type of extraction	Duration and type of treatment	Study outcome	Short methodology
Rosella with stevia As ready-to-brew rosella-stevia bags (i) 5 g rosella powder (ii) 125 mg stevia sweetener Each rosella-stevia tea bag is brewed with 250 mL of boiling water for 5 mins and cooled down for 20–30 min before consuming	14 days treatment (1) Fast for 8 h the night before the first day of treatment, to withdraw participants' blood for fasting blood glucose readings (2) Each participant was given 75 g sugar in 250 mL water and rested for 2 h, for 2nd blood withdrawal as 2-hour post-prandial blood glucose (3) Treatment group (i) (i) Ready-to-brew rosella-stevia tea 2x per day for 14 days	Post-treatment Tea consumption significantly lower FBG level but not the 2-hour PBG level	Venous blood samples were collected for FBG and 2-hour PBG
<i>M. charantia</i> (Bitter melon) <i>As charantia ampalaya</i> capsules vs. placebo capsules	3-month treatment: (1) <i>M. charantia</i> capsules or placebo: (i) 2 capsules, 3 times per day after meals for 3 months (ii) Monthly follow up	No significant effect on mean FBG, total cholesterol, and weight or serum creatinine, ALT, AST, sodium, and potassium	Each monthly visit: (i) Capillary blood sugar levels (ii) Interviewed on compliance and adverse events (iii) Diet and medications reinforced Lab test: (i) HbA1C (ii) Fasting blood glucose (iii) Serum cholesterol (i)WeightExtra: (i) Serum creatinine, AST, ALT, sodium, potassium Adverse event Evaluated every 2 weeks
<i>Curcuma longa</i> (turmeric) with <i>A. sativum L.</i> (garlic) (1) AC group: (i) 200 mg of turmeric ethanolic extract, 200 mg of	For 12-week treatment: (1) AC group: (i) 2.4 g Allium curcuma capsules (ii) 2 times, 3 capsules per day after meal	(i) Significant decrease in FBG of AC group (192.76 vs. 141.71 mg/dL) and 2 h postprandial blood (ii) Significant decrease in	(i) Fasting blood glucose (ii) 2 h postprandial (iii) Lipid profile examination

(continued on next page)

Table 3 (continued)

Plant name and type of extraction	Duration and type of treatment	Study outcome	Short methodology
garlic aqueous extract Vs. Oral drug (ii) 5 mg glibenclamide	(2) Glibenclamide group: (i) 2 times 3 capsules per day (ii) But for the morning-after meal, each consumed 1 capsule of 5 mg	HbA1C 10.41 vs. 8.09)	Oral drug (i) HbA1C. Fasting insulin, liver function, renal function, complete hematology, urine, and heart function

16.2. *Aloe vera*

Aloe vera extract was examined in stz-induced diabetic mice and mouse embryonic NH/3T3 cells [196]. When an extract was given to rats at a dose of 130 mg/kg per day for four weeks, blood glucose, triglycerides, LDL cholesterol, and total cholesterol were all significantly reduced, a result that was comparable to that of metformin. Furthermore, this study discovered that a lyophilized aqueous aloe extract (1 mg/mL) increased the synthesis of GLUT-4 mRNA in NIH/3T3 cells, which was previously unknown. Many studies show that *Aloe vera* extract improved pancreatic-cell function and insulin secretion while restoring pancreatic islet mass in stz-induced diabetes [197].

16.3. *Amaranthus tricolor* (Amaranthaceae)

In the OGTT test, methanolic extracts of the whole plant of *Amaranthus tricolor* were delivered at a different dosage one hour before glucose delivery [14]. Anti-hyperglycemic action in glucose-loaded mice was shown to be substantial at every dosage the largest effect recorded at the maximal dose tested and an effect comparable to glibenclamide.

16.4. *Anacardium occidentale*

Anacardium occidentale was found to reduce blood glucose levels in diabetic rats produced with streptozotocin [198]. It was given twice a day to the rats, beginning two days before the injection of stz. Prior treated rats had considerably lower blood glucose levels than diabetic control rats three days following streptozotocin treatment. Streptozotocin-induced diabetic rats received a defined dose of methanol extract, and their blood glucose levels decreased, showing effects similar to those of the conventional medication Pioglitazone [109].

16.5. *Barleria prionitis*

Alloxan-induced diabetic rats showed anti-diabetic action of *Barleria prionitis* leaves ethanolic extraction [199]. Leave extracts reduced glycosylated hemoglobin and blood glucose levels in animals. Serum insulin and hepatic lipogen levels were also elevated.

16.6. *Bauhinia thoningii* (Fabaceae)

It was discovered in a study on alloxan-induced diabetic rats [200] that *Bauhinia thoningii* plant leaves extract in water form has an anti-diabetic effect. Using an oral dose, the extract caused a substantial reduction in blood glucose, low-density lipoprotein cholesterol, and heart disease in the participants.

16.7. *Camellia sinensis* (Theaceae)

Mice with diabetes caused by streptozotocin were given the crude tea

leaf extract from *Camellia sinensis* to test for hypoglycemic action [201]. Diabetes rats were fed tea for 20–25 days, and the hypolipidemic and anti-hyperglycemic effects were seen. Other benefits were a decrease in body weight and the return to normal of several abnormal hematobiochemical markers.

16.8. *Moringa oleifera* (Moringaceae)

Experiments on diabetic rats were conducted to examine the anti-diabetic and antioxidative effects of *Moringa oleifera* methanol extracts [202]. Nitric oxide and serum glucose levels dropped significantly at both doses, whereas protein and insulin levels rose. Even more remarkable, a histologic study of the pancreas revealed considerable islet cell histoarchitectural repair after therapy with *Moringa oleifera*. *Moringa oleifera* leaves have been shown to have a hypoglycemic impact and prevent weight loss in rats that have been given alloxan [203].

16.9. *Murraya koenigii* (Rutaceae)

Alloxan-induced diabetic mice were given Water extraction of *Murraya koenigii* leaf were given to alloxan-induced diabetic rats and the results showed that the extract had a substantial influence on blood sugar levels also carbohydrate metabolism [204]. Furthermore, an ethanolic extract of this plant has been shown to alleviate dexamethasone developed hyperglycemia and resistance to insulin as a result of increased skeletal muscle glucose absorption. [205].

16.10. *Opuntia ficus-indica* (Cactaceae)

Researchers tested a conventional drug on the treated group (streptococci-induced diabetes) (dimethyl biguanide, 100 mg/kg) and an edible *Opuntia ficus-indica* extraction on those same diabetic animals [206]. All but the aqueous extract drastically lowered blood glucose levels while preserving body weight. Reduced fasting sugar levels were the primary benefit of using petroleum ether extraction.

16.11. *Origanum vulgare* (Lamiaceae)

Extraction of the *Origanum vulgare* demonstrated substantial phenol content and in vitro antioxidant activity in DPPH tests [207]. To test the extract in humans, researchers used stz - induced diabetic rats. The methanol extracts had anti-inflammatory and cytoprotective properties.

16.12. *Momordica saponins*

Momordica saponins improve uric acid and creatinine levels in STZ-induced T2DM rats, while MCP improves antioxidant capacity [208]. In STZ-induced diabetic rats, *Momordica saponins* reduce oxidative stress and regulate the HO-1/Nrf2 pathway [209]. MC extract protects kidneys from oxidative damage, prolonging diabetic nephropathy [210]. Conversely, a bitter gourd diet prevents renal problems by reducing glycoconjugates and increasing heparan sulfate in diabetics [211]. Another study found that MC extract reduces retinal ganglion cell death in T2DM rats by decreasing Bax and increasing Bcl-2 mRNA and protein expression [212]. Also, *Momordica saponin* [208], MC ethanol extract [213], and MC leaf extract [109] have hypo-lipidemic action. MC seeds may lower blood lipids and uric acid levels [214].

16.13. *Catharanthus rose*

The Apocynaceae family includes *Catharanthus roseus*, an ever-blooming herb. There is a considerable effect on the lipid profile and insulin sensitivity of *Catharanthus roseus* leaf extract [215]. Diabetes-related blood glucose levels were significantly reduced in diabetic mice treated with ethanolic extract of *Catharanthus roseus* (200 mg/kg b.w) in the present study. Alloxan was administered to start

the body's insulin production. Diabetic animals received leaf extract from *Catharanthus roseus*. In rats, the aqueous extract solution of *Catharanthus roseus* was given for 60 days and significantly reduced glucose levels [216]. It was shown that *Catharanthus roseus* suspension had a substantial effect on diabetes. The long-term usage of *Catharanthus roseus* prevents insulin resistance in the body, according to a study. Pre-diabetic patients may benefit from using *Catharanthus roseus* as a supplement to prevent or control insulin resistance [217].

16.14. *Anacardium occidentale*

Because the entire tree produces resources and goods, *Anacardium occidentale* is considered a multipurpose tree. Medicinal uses include the leaf, bark, root, and nutshell oil [218]. Hyperglycemia is a hallmark of diabetes, and the oxidative stress that results from it is a major cause for concern because it can lead to a wide range of issues. antihyperglycemic and antioxidant properties of *A. occidentale* root extracts have been studied. Analyses of cytotoxicity and antidiabetic potential were carried out on MIN6 pancreatic β -cells using MTT assay and ELISA at a higher glucose concentration. qRT PCR was used to investigate the impact of 80% MAO on INS gene expression. Antihyperglycemic and antioxidative capabilities of *A. occidentale* root extracts were found to be efficient in this investigation, along with the ability to normalize the insulin secretory system of β -cells. This material's active principles and in vivo effects in *A. Occidentale* root extracts need to be further investigated. It is hoped that the root extracts of *A. occidentale* would yield new medication leads for the treatment of diabetes [219].

16.15. *Syzygium cumini*

Myrtaceae is a family of plants that includes the *Syzygium cumini* tree, often known as Eugenia jambolana. Antidiabetic effects of SC seed extracts and mycaminose compound were evaluated in this study. The blood sugar levels of diabetic rats decreased significantly after 15 days of therapy with extracts of SC. According to these findings, the traditional usage of SC seed as an anti-diabetic has been proven by modern research. Inhibition of insulin production from BETA-cells in the islets of Langerhans may be one method by which seeds lower blood sugar levels by boosting insulin secretion from the pancreas or releasing insulin from its bound state. The insulin-release stimulatory properties of a variety of different plants have been documented to produce hypoglycemic effects. This study's findings support the traditional usage of *S. cumini* seed in Indian medicine to treat diabetes [220].

16.16. *Lupinus albus L*

Lupinus albus L. seed proteins are expected to release some of the bioactive peptides that are thought to play a significant role in the progression of cardiovascular disease, type 2 diabetes, and obesity. In general, the seeds contain anything from 6% to 13% oil, 34–39% fibers, and 33–47% proteins [221,222]. Materials containing seeds of *Lupinus albus L.* were obtained from a spice shop and dried in the shade. Before extraction, every seed was roasted and then ground into a powder. After letting the mixture sit for 48 h, 100 g of powder were filtered out of 500 milliliters of ethanol. The ethanol that was extracted was evaporated under a vacuum (at 40 degrees Celsius with a rotating evaporator). The organic solvent evaporation-dried extracts that were made under lower pressure and temperature were kept at a temperature of 4 degrees Celsius until they were used. Before application, 1 milliliter of distilled water was used to dissolve the extract. Animals were given the extract at a dose of 10 mg/kg of body weight through an intragastric tube for 20 days [223]. Glycosylation reduces the synthesis and activity of numerous antioxidant enzymes, namely SOD and GPx. The liver, kidney, and pancreas were normal in the control and LA groups. The STZ group diabetic rats' liver, kidney, and pancreatic tissues showed severe deterioration. The regeneration of the liver, kidney, and pancreas in rats

given *Lupinus albus L.* seed extract and STZ reveals the strong protection conferred by *Lupinus albus L.* seed extract against diabetes. Unlike the STZ group, this group did not show severe deterioration. Increased production of lipid peroxides and ROS causes membrane damage and pathological alterations in the liver, kidney, and pancreas. These findings suggest that *Lupinus albus L.* seed extract may be an anti-diabetic, antioxidant, and anti-oxidant. Extract after roasting *Lupinus albus* seed is a pioneer in literature and ethnomedicine for diabetes [223].

16.17. *Tecoma stans*

Herbarium mixtures have been used empirically, and their qualities are unknown. The purpose of this study was to see how the oral administration of a herbarium mixture (*Guazuma ulmifolia* [*G. ulmifolia*]/*Tecoma stans* [*T. stans*]) affected individuals with type 2 diabetes mellitus metabolic profile (T2DM). In 40 T2DM patients, a randomly selected, double-blind, placebo-controlled clinical trial was conducted. They were between the ages of 40 and 65, with a BMI of 25.0–34.9 kg/m² and an HbA1c of > 7.0%. The following measurements were taken: BMI, mass index, fasting blood glucose, HbA1c, lipids, kidney, and liver function. For 90 days, the patients were given either the herbarium combo (*G. ulmifolia*/*T. stans*) before each meal that enhanced the glycemic profile in T2DM patients. This clinical trial supports the traditional usage of *G. ulmifolia*/*T. stans* in the treatment of T2DM by demonstrating that the combination of these phytopharmaceuticals can lower glucose and HbA1c in patients with T2DM. This type of clinical investigation must be continued with larger sample numbers for longer periods to determine its effectiveness and long-term safety [224].

16.18. *Taraxacum officinale*

Herbs and their mixtures might impact many links of the pathogenic system of diabetes mellitus or its consequences due to their extensive variety of biologically active compounds. One of these combinations is an antidiabetic herbal mixture containing an insulin-containing component – *Taraxacum officinale L.* roots – that has been shown to have hypoglycemic, hypolipidemic, antioxidant, hepatoprotective, and pancreatoprotective activity in previous pharmacological studies in vivo. The goal of this study was to find out how much inulin and fructans there were in *Taraxacum officinale L.* The difference between fructose, a product of enzymatic hydrolysis, and D-fructose, a constituent of sucrose and free D-fructose, as well as the empirical factor for the conversion of D-fructose from inulin, was used to calculate the quantity content of inulin. After conversion into volatile derivatives like aldononitrile acetate, carbohydrates employed in the computation of inulin were separated by gas chromatography-mass spectrometry. *Taraxacum officinale L.* roots contain 436.29 mg/g of inulin, according to the findings. As a result of acid hydrolysis of 5-(hydroxymethyl)furfural, the total concentration of fructans was measured by spectrophotometric analysis. The roots of *Taraxacum officinale L.* contain 39.49% fructans, according to the findings. The findings show that this plant component should be included in herbal antidiabetic mixtures since it has hypoglycemic, hypolipidemic, and detoxifying properties due to the presence of fructans and inulin [225].

16.19. *Black carrot*

The Type 2 diabetes healing properties of black carrots are due to the presence of phenol in them. The goal of this research is to figure out how phenol interacts with enzymes that might act against diabetes. Pure extraction of black carrot and the conventional inhibitors acarbose and vildagliptin, respectively, were used in an in vitro experiment on glucosidase, amylase, and DPP-IV inhibition. For a better understanding of interactions, the inhibitory activity of chosen phenolic compounds was investigated using in silico docking with all three enzymes. In addition, pure black carrot extract was encapsulated. The purified

extract had a higher in vitro IC50 value than the usual inhibitors acarbose for α -amylase and α -glucosidase, and vildagliptin for DPP-IV. Similarly, the docking scores of a few anthocyanin compounds were found to be greater than those of their inhibitors, implying that the inhibition was more effective. Among the anthocyanin compounds present in black carrots, cyanidin 3-xylosyl galactoside was discovered to be a possible medication to block these enzymes, whereas dipeptidyl peptidase IV was revealed to be the greatest target for the controlling diabetes with anthocyanins. Anthocyanins from black carrots have been found to help regulate diabetes, and for the first time, we propose that cyanidin 3-xylosyl galactoside is the best prospective molecule for inhibiting glucose metabolism enzymes. The work also demonstrates the use of α -cyclodextrin to encapsulate anthocyanin pigments [226].

17. Conclusions and future directions

Herbal plants have utilization to treat communicable and non-communicable illnesses. At present many effective medicines are produced from naturally generated lead compounds or acquired directly from plant sources. Scientific interest in the plant's product in drug discovery and development has resurfaced, indicating that it could be a prime source of novel medicines in the future. A lot of innovative techniques have been developed as a result of medicinal chemists' interest in natural product drug discovery. These innovative approaches have the potential to reduce the technical limitations of natural product development while also addressing the obstacles that come with discovering and developing novel natural products due to their complicated nature. Technological advancements allowed researchers to investigate the phytoconstituents, resulting in the isolation or synthesis of several successful medicinal medications and innovative lead compounds that potentially serve as a foundation for future drugs. For good results in this area, it is very vital to take a cross-disciplinary attitude that includes traditional and pharmacological knowledge, phytochemistry, botany, analytical chemistry, appropriate biological screening methodologies, and modern drug development tools. Innovative natural product marketing strategies; the use of novel compounds from plants and chemical libraries based on natural products will be expanded in the drug discovery process in the future, reducing hurdles and improving success rates. It has the potential to make a significant contribution to the creation of novel drugs and the resolution of global health issues.

Diabetes is a severe public health issue, but there is good news: significant progress is being made in diabetes prevention, detection, and treatment. Patients with type 1 diabetes must take insulin 3–4 times a day for the rest of their life, and their blood sugar levels must be closely checked to avoid consequences such as retinopathy and cardiovascular disease risks. Around 1300 patients with type 1 diabetes are predicted to receive a whole organ (pancreas) transplant and no longer require insulin, however demand for organ transplantation outnumbers supply. Rejection of the transplanted organ is another risk factor; as a result, the patient is given powerful immunosuppressive medicines, which can lead to additional catastrophic disorders. Glycemic control must be closely managed in the treatment of type 2 diabetes. Controlling the progressive decline of β cell function is critical because it can lead to glycemic control loss. Conventional medicines and insulin can help, but they can't fix the underlying metabolic and gluco-regulatory issues. Diabetes is becoming more prevalent every day, necessitating aggressive and focused combinational medication, notably incretin-based therapy and peptide analogs. This may help to restore and maintain β cell function while also slowing the progression of type 2 diabetes. In today's world, a new drug's usefulness and success will be determined by its capacity to treat/relieve one or more metabolic abnormalities, such as increased insulin production or improved glucose absorption and utilization by peripheral tissues, notably skeletal muscle.

Aside from novel therapeutic generations, numerous other classes have been described as alternative ways of treating diabetes, either

alone or in combination. The future of leptin therapy is one of the newest concepts in diabetes management. It's a hormone produced by adipocytes that affects the central nervous system's neurons. This hormone has various functions, including preventing excessive weight gain by reducing food intake and increasing energy expenditure. Leptins also activate leptin receptors (LEPRs), which regulate glucose homeostasis. With reference to type 1 diabetes, it has been established that the central nervous system modulates leptins' sugar-lowering effect; it was hypothesized that leptins' antidiabetic action could have been affected by neurons in the brain. In mice with insulin-deficient type 1 diabetes, leptin treatment improves their condition through CNS-dependent pathways. Designing and using mucoadhesive microcapsules of various medications, such as glipizide, to enable controlled drug release and successful targeting is another area of drug development. Mucoadhesion is a unique strategy in drug delivery design because it causes the drug to release slowly at the action or absorption site, enhancing the drug's interaction with the underlying tissue forms and thereby increasing drug bioavailability. The number of drug delivery techniques that have been tried as a possible diabetes treatment is endless. Transdermal insulin delivery (which was developed as a result of painful and difficult insulin therapy) maintains stable insulin levels without the insulin deposits that are common with subcutaneous insulin injections. Odegaard and colleagues discovered that activated macrophages have a beneficial function in the regulation of nutritional homeostasis, implying that polarizing macrophages to the alternate state could be a valuable option in the treatment of type 2 diabetes. Clinical advances have been achieved in the prevention, development, and treatment of the condition, but no therapeutic strategy has yet proven to be effective. With new technologies altering treatment options, finding an effective drug will not be difficult. Extensive research that led to the discovery of disease-causing pathway genes and the sequencing of entire genomes has changed diabetes research. The introduction of tools such as PCRs, DNA microarrays, and gene knockouts with silence has opened up a new field in identifying faulty genes/mutations in an organism's genome. The rising prevalence of diabetes around the world is putting a financial strain on each country's economy. Diabetes, unlike some other diseases, has a treatment that, when properly managed, can significantly reduce complications such as heart attacks, amputations, blindness, and kidney failure. With constant research, finding the proper therapy for diabetes treatment is not impossible.

Diabetes and its consequences are currently on the rise throughout the world, and it is projected to climb much further in the future. Plant-based remedies, particularly traditional medicinal mixes, have been stressful in the treatment of diabetes, despite the availability of anti-diabetic medicines. As a result, traditional plant-derived bioactive chemical treatments for diabetes are currently being promoted due to their safety and lack of adverse effects when compared to manufactured drugs. These investigations will greatly aid research into the discovery of antidiabetic medications from innovative natural product leads utilizing medicinal chemistry methodologies, as well as the exploration of their mechanistic activities via pharmacological studies.

As a result, this study briefly summarizes the active components and pharmacological effects of various commonly used plants in diabetes treatment. Furthermore, herbal extracts can now be used with conventional pharmaceuticals for combinatorial therapy. Each herb has its unique components that can help reduce diabetic complications and lower blood sugar levels. The goal of this review is to provide the required information for diabetes management. We have provided a comprehensive list of anti-diabetic herbs in our review. The isolation and identification of bioactive phytochemicals from these plants will help researchers better understand how to build anti-diabetic functional foods and drugs. The mechanism of action of the reported phytochemicals and/or plant extracts attributed to antidiabetic activity has also been discussed in order to focus on the potential phytochemicals and phytosources for further studies in the discovery and development of novel antidiabetic therapies.

Funding

No funding was used in this study.

CRedit authorship contribution statement

Authors have written their respective part in the paper therefore, all the authors have equally contributed to this paper under the supervision of Prof. Dr. Abdur Rauf.

Data Availability

Available data are presented in the manuscript.

Acknowledgment

The authors are grateful to the Department of Pharmacy, Daffodil International University for permitting to conduct the research and all sorts of supports.

Conflicts of interest

The authors declare no conflict of interest.

Conflict of interest

We declare no conflict of interest in submission of this manuscript.

References

- [1] A.T. Kharroubi, H.M. Darwish, Diabetes mellitus: the epidemic of the century, *World J. Diabetes* 6 (2015) 850, <https://doi.org/10.4239/WJD.V6.I6.850>.
- [2] D. Ard, N.-S. Tettey, S. Feresu, The influence of family history of type 2 diabetes mellitus on positive health behavior changes among African Americans, *Int. J. Chronic Dis.* 2020 (2020) 1–8, <https://doi.org/10.1155/2020/8016542>.
- [3] H. Das, B. Naik, H.S. Behera, Classification of diabetes mellitus disease (DMD): a data mining (DM) approach, *Adv. Intell. Syst. Comput. 710* (2018) 539–549, https://doi.org/10.1007/978-981-10-7871-2_52.
- [4] C. Gilor, S.J.M. Niessen, E. Furrow, S.P. DiBartola, What's in a name? Classification of diabetes mellitus in veterinary medicine and why it matters, *J. Vet. Intern. Med.* 30 (2016) 927–940, <https://doi.org/10.1111/JVIM.14357>.
- [5] A. Ahmed, A. Rauf, H.A. Hemeg, M.N. Qureshi, R. Sharma, A.S.M. Aljohani, F. A. Alhumaydhi, I. Khan, A. Alam, M.M. Rahman, Green synthesis of gold and silver nanoparticles using *Opuntia dillenii* aqueous extracts: characterization and their antimicrobial assessment, *J. Nanomater.* 2022 (2022) 1–17, <https://doi.org/10.1155/2022/4804116>.
- [6] S. Chatterjee, K. Khunti, M.J. Davies, Type 2 diabetes, *Lancet* 389 (2017) 2239–2251, [https://doi.org/10.1016/S0140-6736\(17\)30058-2](https://doi.org/10.1016/S0140-6736(17)30058-2).
- [7] E. Chiefari, B. Arcidiacono, D. Foti, A. Brunetti, Gestational diabetes mellitus: an updated overview, *J. Endocrinol. Invest.* 40 (2017) 899–909, <https://doi.org/10.1007/S40618-016-0607-5>.
- [8] A. Adler, P. Bennett, S. Colagiuri Chair, E. Gregg, K. Venkat Narayan, M. Inês Schmidt, E. Sobngwi, N. Tajima, N. Tandon, N. Unwin, S. Wild, J. Yudkin, N. Levitt, V. Mohan, S. Montgomery, M.J. Nyirenda, J. Tuomilehto, S. Den Boon, S. Hocking, Reprint of: classification of diabetes mellitus, *Diabetes Res. Clin. Pract.* (2021), 108972, <https://doi.org/10.1016/J.DIABRES.2021.108972>.
- [9] Z. Tao, A. Shi, J. Zhao, Epidemiological perspectives of diabetes, *Cell Biochem. Biophys.* 73 (2015) 181–185, <https://doi.org/10.1007/S12013-015-0598-4>.
- [10] F. Chentli, S. Azzoug, S. Mahgoun, Diabetes mellitus in elderly, *Indian J. Endocrinol. Metab.* 19 (2015) 744, <https://doi.org/10.4103/2230-8210.167553>.
- [11] M.N. Piero, G.M. Nزارو, J.M. Njagi, Q.R. Code for Mobile users Diabetes mellitus—a devastating metabolic disorder, *Asian J. Biomed. Pharm. Sci.* 2014 (2015) 1–7, <https://doi.org/10.15272/ajbps.v4i40.645>.
- [12] K.C. Chhinsebu, Diabetes mellitus and nature's pharmacy of putative antidiabetic plants, *J. Herb. Med.* 15 (2019), 100230, <https://doi.org/10.1016/J.HERMED.2018.09.001>.
- [13] R. Ghosh Tarafdar, S. Nath, A. Das Talukdar, M. Dutta Choudhury, Antidiabetic plants used among the ethnic communities of Unakoti district of Tripura, India *J. Ethnopharmacol.* 160 (2015) 219–226, <https://doi.org/10.1016/J.JEP.2014.11.019>.
- [14] B. Salehi, A. Ata, N.V.A. Kumar, F. Sharopov, K. Ramírez-Alarcón, A. Ruiz-Ortega, S.A. Ayatollahi, P.V.T. Fokou, F. Kobarfard, Z.A. Zakaria, M. Iriti, Y. Taheri, M. Martorell, A. Sureda, W.N. Setzer, A. Durazzo, M. Lucarini, A. Santini, R. Capasso, E.A. Ostrander, M.I. Atta-ur-Rahman, W.C. Choudhary, J. Cho, Sharifi-Rad, Antidiabetic potential of medicinal plants and their active components, *Biomolecules* 9 (2019) 551, <https://doi.org/10.3390/BIOM9100551>.
- [15] C.M. Naidoo, Y. Naidoo, Y.H. Dewir, H.N. Murthy, S. El-Hendawy, N. Al-Suhaibani, Major bioactive alkaloids and biological activities of *Tabernaemontana* species (Apocynaceae), *Plants* 10 (2021) 313, <https://doi.org/10.3390/PLANTS10020313>.
- [16] H. Zhang, Y. Ben, Y. Han, Y. Zhang, Y. Li, X. Chen, Phthalate exposure and risk of diabetes mellitus: implications from a systematic review and meta-analysis, *Environ. Res.* 204 (2022), 112109, <https://doi.org/10.1016/J.ENVRES.2021.112109>.
- [17] S. Sekhon-Loody, H.P.V. Rupasinghe, Evaluation of antioxidant, antidiabetic and antiobesity potential of selected traditional medicinal plants, *Front. Nutr.* 6 (2019), <https://doi.org/10.3389/FNUT.2019.00053/FULL>.
- [18] M. El-Amir, F. Hegazy, P.W. Pare, M.A.A. Ibrahim, A. Najmi, S.A. Javed, M. Al Bratty, H.A. Alhazmi, Modern approaches in the discovery and development of plant-based natural products and their analogues as potential therapeutic agents, *Molecules* 27 (2022) 349, <https://doi.org/10.3390/MOLECULES27020349>.
- [19] C.G. Kato-Schwartz, R.C.G. Corrêa, D. de Souza Lima, A.B. de Sá-Nakanishi, G. de Almeida Gonçalves, F.A.V. Seixas, C.W.I. Haminiuk, L. Barros, I.C.F.R. Ferreira, A. Bracht, R.M. Peralta, Potential anti-diabetic properties of Merlot grape pomace extract: an in vitro, in silico and in vivo study of α -amylase and α -glucosidase inhibition, *Food Res. Int.* 137 (2020), 109462, <https://doi.org/10.1016/J.FOODRES.2020.109462>.
- [20] H. Dehghan, Y. Sarrafi, P. Salehi, Antioxidant and antidiabetic activities of 11 herbal plants from Hyrcania region, Iran, *J. Food Drug Anal.* 24 (2016) 179–188, <https://doi.org/10.1016/J.JFDA.2015.06.010>.
- [21] M.N. Sarian, Q.U. Ahmed, S.Z. Mat So'Ad, A.M. Alhassan, S. Murugesu, V. Perumal, S.N.A. Syed Mohamad, A. Khatib, J. Latip, Antioxidant and antidiabetic effects of flavonoids: a structure-activity relationship based study, *Biomed. Res. Int.* 2017 (2017), <https://doi.org/10.1155/2017/8386065>.
- [22] H. Nasri, H. Shirzad, A. Baradaran, M. Rafieian-kopaei, Antioxidant plants and diabetes mellitus, *J. Res. Med. Sci.* 20 (2015) 491, <https://doi.org/10.4103/1735-1995.163977>.
- [23] C. Zhao, C. Yang, S.T.C. Wai, Y. Zhang, M.P. Portillo, P. Paoli, Y. Wu, W. San Cheang, B. Liu, C. Carpené, J. Xiao, H. Cao, Regulation of glucose metabolism by bioactive phytochemicals for the management of type 2 diabetes mellitus, *Crit. Rev. Food Sci. Nutr.* 59 (2019) 830–847, <https://doi.org/10.1080/10408398.2018.1501658>.
- [24] D. Lin, M. Xiao, J. Zhao, Z. Li, B. Xing, X. Li, M. Kong, L. Li, Q. Zhang, Y. Liu, H. Chen, W. Qin, H. Wu, S. Chen, An overview of plant phenolic compounds and their importance in human nutrition and management of type 2 diabetes, *Molecules* 21 (2016) 1374, <https://doi.org/10.3390/molecules21101374>.
- [25] H. Ardalani, F. Hejazi Amiri, A. Hadippanah, K.T. Kongstad, Potential antidiabetic phytochemicals in plant roots: a review of in vivo studies, *J. Diabetes Metab. Disord.* 20 (2021) 1837–1854, <https://doi.org/10.1007/S40200-021-00853-9>.
- [26] N. Tran, B. Pham, L. Le, Bioactive compounds in anti-diabetic plants: from herbal medicine to modern drug discovery, *Biology* 9 (2020) 252, <https://doi.org/10.3390/BIOLOGY9090252>.
- [27] K.G.P. Wasana, A.P. Attanayake, K.A.P.W. Jayatilaka, T.P. Weeraratna, Antidiabetic activity of widely used medicinal plants in the Sri Lankan traditional healthcare system: new insight to medicinal flora in Sri Lanka, *Evid. Based Complement Altern. Med.* 2021 (2021), <https://doi.org/10.1155/2021/6644004>.
- [28] P. Jain, A.M. Joshi, S. Mohanty, Everything You Wanted to Know About Noninvasive Glucose Measurement and Control, (2021). <https://doi.org/10.1109/MCE.2021.3073498>.
- [29] P.E. MacDonald, P. Rorsman, Oscillations, intercellular coupling, and insulin secretion in pancreatic β cells, *PLoS Biol.* 4 (2006) 167–171, <https://doi.org/10.1371/JOURNAL.PBIO.0040049>.
- [30] P.F. Egea, R.M. Stroud, P. Walter, Targeting proteins to membranes: structure of the signal recognition particle, *Curr. Opin. Struct. Biol.* 15 (2005) 213–220, <https://doi.org/10.1016/J.SBI.2005.03.007>.
- [31] Shu Jin Chan, P. Keim, D.F. Steiner, Cell free synthesis of rat preproinsulins: characterization and partial amino acid sequence determination, *Proc. Natl. Acad. Sci. U.S.A.* 73 (1976) 1964–1968, <https://doi.org/10.1073/PNAS.73.6.1964>.
- [32] P.T. Lomedico, S.J. Chan, D.F. Steiner, G.F. Saunders, Immunological and chemical characterization of bovine preproinsulin, *J. Biol. Chem.* 252 (1977) 7971–7978, [https://doi.org/10.1016/S0021-9258\(17\)40921-5](https://doi.org/10.1016/S0021-9258(17)40921-5).
- [33] C. Patzelt, A.D. Labrecque, J.R. Duguid, R.J. Carroll, P.S. Keim, R.L. Heinrikson, D.F. Steiner, Detection and kinetic behavior of preproinsulin in pancreatic islets, *Proc. Natl. Acad. Sci. U.S.A.* 75 (1978) 1260–1264, <https://doi.org/10.1073/PNAS.75.3.1260>.
- [34] X.F. Huang, P. Arvan, Intracellular transport of proinsulin in pancreatic β -Cells: structural maturation probed by disulfide accessibility, *J. Biol. Chem.* 270 (1995) 20417–20423, <https://doi.org/10.1074/JBC.270.35.20417>.
- [35] S. Munro, H.R.B. Pelham, A C-terminal signal prevents secretion of luminal ER proteins, *Cell* 48 (1987) 899–907, [https://doi.org/10.1016/0092-8674\(87\)90086-9](https://doi.org/10.1016/0092-8674(87)90086-9).
- [36] D.F. Steiner, J.L. Clark, C. Nolan, A.H. Rubenstein, E. Margoliash, B. Aten, P. E. Oyer, Proinsulin and the biosynthesis of insulin, *Recent Prog. Horm. Res.* 25 (1969) 207–282, <https://doi.org/10.1016/B978-0-12-571125-8.50008-9>.
- [37] V. Poytout, D. Hagman, R. Stein, I. Artner, R.P. Robertson, J.S. Harmon, Regulation of the insulin gene by glucose and fatty acids, *J. Nutr.* 136 (2006) 873–876, <https://doi.org/10.1093/JN/136.4.873>.
- [38] S.J. Giddings, J. Chirgwin, M.A. Permutt, Effects of glucose on proinsulin messenger RNA in rats in vivo, *Diabetes* 31 (1982) 624–629, <https://doi.org/10.2337/DIAB.31.7.624>.

- [39] M. Welsh\$, D.A. Nielseng, A.J. Mackrelli, D.F. Steinerll, M. Welsh, N. Scherberg, R. Gilmore, D.F. Steiner, Control of insulin gene expression in pancreatic beta-cells and in an insulin-producing cell line, RIN-5F cells. II. Regulation of insulin mRNA stability, *J. Biol. Chem.* 260 (1985) 13590–13594, [https://doi.org/10.1016/S0021-9258\(17\)38765-3](https://doi.org/10.1016/S0021-9258(17)38765-3).
- [40] R.H. Knopp, R.O. Bergelin, P.W. Wahl, C.E. Walden, Relationships of infant birth size to maternal lipoproteins, apoproteins, fuels, hormones, clinical chemistries, and body weight at 36 weeks gestation, *Diabetes* 34 (1985) 71–77, <https://doi.org/10.2337/DIAB.34.2.S71>.
- [41] K.P. Knoch, R. Meisterfeld, S. Kersting, H. Bergert, A. Altkrüger, C. Wegbrod, M. Jäger, H.D. Saeger, M. Solimena, cAMP-dependent phosphorylation of PTB1 promotes the expression of insulin secretory granule proteins in β cells, *Cell Metab.* 3 (2006) 123–134, <https://doi.org/10.1016/j.cmet.2005.12.008>.
- [42] M.B. Soares, E. Schon, A. Henderson, S.K. Karathanasis, R. Cate, S. Zeitlin, J. Chirgwin, A. Efstratiadis, RNA-mediated gene duplication: the rat preproinsulin I gene is a functional retroposon, *Mol. Cell. Biol.* 5 (1985) 2090–2103, <https://doi.org/10.1128/MCB.5.8.2090-2103.1985>.
- [43] D. Hanahan, Heritable formation of pancreatic β -cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes, *Nature* 315 (1985) 115–122, <https://doi.org/10.1038/315115a0>.
- [44] D. Bucchini, M.A. Ripoche, M.G. Stinnakre, P. Desbois, P. Lorès, E. Monthioux, J. Absil, J.A. Lepesant, R. Pictet, J. Jami, Pancreatic expression of human insulin gene in transgenic mice, *Proc. Natl. Acad. Sci. U.S.A.* 83 (1986) 2511–2515, <https://doi.org/10.1073/PNAS.83.8.2511>.
- [45] D.T. Crowe, M.-J. Tsai, Mutagenesis of the rat insulin II 5'-flanking region defines sequences important for expression in HIT cells, *Mol. Cell. Biol.* 9 (1989) 1784–1789, <https://doi.org/10.1128/MCB.9.4.1784-1789.1989>.
- [46] T. Edlund, M.D. Walker, P.J. Barr, W.J. Rutter, Cell-specific expression of the rat insulin gene: evidence for role of two distinct 5' flanking elements, *Science* 230 (1985) 912–916, <https://doi.org/10.1126/SCIENCE.3904002>.
- [47] D. Melloul, Y. Ben-Neriah, E. Cerasi, Glucose modulates the binding of an islet-specific factor to a conserved sequence within the rat I and the human insulin promoters, *Proc. Natl. Acad. Sci. U.S.A.* 90 (1993) 3865–3869, <https://doi.org/10.1073/PNAS.90.9.3865>.
- [48] A. Sharma, R. Stein, Glucose-induced transcription of the insulin gene is mediated by factors required for beta-cell-type-specific expression, *Mol. Cell. Biol.* 14 (1994) 871–879, <https://doi.org/10.1128/MCB.14.2.871-879.1994>.
- [49] J. Whelan, D. Poon, P.A. Weil, R. Stein, Pancreatic beta-cell-type-specific expression of the rat insulin II gene is controlled by positive and negative cellular transcriptional elements, *Mol. Cell. Biol.* 9 (1989) 3253–3259, <https://doi.org/10.1128/MCB.9.8.3253-3259.1989>.
- [50] Z. Fu, E.R. Gilbert, D. Liu, Regulation of insulin synthesis and secretion and pancreatic beta-cell dysfunction in diabetes, *Curr. Diabetes Rev.* 9 (2012) 25–53, <https://doi.org/10.2174/157339913804143225>.
- [51] P. Marchetti, M. Bugliani, V.D. De Tata, M. Suleiman, L. Marselli, Pancreatic beta cell identity in humans and the role of type 2 diabetes, *Front. Cell Dev. Biol.* 5 (2017) 55, <https://doi.org/10.3389/FCELL.2017.00055/BIBTEX>.
- [52] M. Przeor, Some common medicinal plants with antidiabetic activity, known and available in Europe (A Mini-Review), *Pharmaceuticals* 15 (2022) 65, <https://doi.org/10.3390/PH15010065>.
- [53] A.K. Asekunowo, A.O.T. Ashafa, O. Okoh, O.T. Asekun, O.B. Familoni, Polyphenolic constituents, antioxidant and hypoglycaemic potential of leaf extracts of *Acalypha godseffiana* from Eastern Nigeria: in vitro study, *J. Med. Plants Econ. Dev.* 3 (2019), <https://doi.org/10.4102/JOMPED.V3I1.36>.
- [54] A. Hosseini, H. Hosseinzadeh, A review on the effects of *Allium sativum* (Garlic) in metabolic syndrome, *J. Endocrinol. Investig.* 38 (2015) 1147–1157, <https://doi.org/10.1007/S40618-015-0313-8>.
- [55] A. Muniz-Ramirez, R.M. Perez, E. Garcia, F.E. Garcia, Antidiabetic activity of aloe vera leaves, *Evid. Based Complement Altern. Med* 2020 (2020), <https://doi.org/10.1155/2020/6371201>.
- [56] T. Balasubramanian, M. Karthikeyan, K.P. Muhammed Anees, C.P. Kadeeja, K. Jaseela, Antidiabetic and antioxidant potentials of *Amaranthus hybridus* in streptozotocin-induced diabetic rats, *J. Diet Suppl.* 14 (2017) 395–410, <https://doi.org/10.1080/19390211.2016.1265037>.
- [57] R. Lamichhane, P.R. Pandeya, K.-H. Lee, S.-G. Kim, D.R. Kandel, H.-J. Jung, *Angioperis helferiana*, a fern with great potential medicinal value: anti-dipogenic, anti-inflammatory, and anti-diabetic activity, *Pharmacogn. Mag.* 15 (2019) 423, <https://doi.org/10.4103/PM.PM.430.18>.
- [58] M.Y. Musdja, A. Nurdin, A. Musir, Antidiabetic effect and glucose tolerance of areca nut (*Areca catechu*) seed ethanol extract on alloxan-induced diabetic male rats, *IOP Conf. Ser. Earth Environ. Sci.* 462 (2020), 012036, <https://doi.org/10.1088/1755-1315/462/1/012036>.
- [59] A. Wm, N. Dw, A. Ds, N. Mp, N. Enm, In Vivo Antidiabetic Effect of Aqueous Leaf Extract of *Azadirachta indica*, A. Juss in Alloxan Induced Diabetic Mice, 2016, <https://doi.org/10.4172/jdcm.1000.106>.
- [60] R. Dheer, P. Bhatnagar, A study of the antidiabetic activity of *Barleria prionitis* Linn, *Indian J. Pharmacol.* 42 (2010) 70–73, <https://doi.org/10.4103/0253-7613.64493>.
- [61] M.S. Pinheiro, L.S. Rodrigues, L.S. Neto, R.Q. Moraes-Souza, T.S. Soares, M. F. Américo, K.E. Campos, D.C. Damasceno, G.T. Volpato, Effect of *Bauhinia holophylla* treatment in Streptozotocin-induced diabetic rats, *Acad. Bras. Cienc.* 89 (2017) 263–272, <https://doi.org/10.1590/0001-3765201720160050>.
- [62] M.S. Pinheiro, L.S. Rodrigues, L.S. Neto, R.Q. Moraes-Souza, T.S. Soares, M. F. Américo, K.E. Campos, D.C. Damasceno, G.T. Volpato, Effect of *Bauhinia holophylla* treatment in Streptozotocin-induced diabetic rats, *Acad. Bras. Cienc.* 89 (2017) 263–272, <https://doi.org/10.1590/0001-3765201720160050>.
- [63] M.T. Islam, C. Quispe, D.M. El-Kersh, M.C. Shill, K. Bhardwaj, P. Bhardwaj, J. Sharifi-Rad, M. Martorell, R. Hossain, A. Al-Harrasi, A. Al-Rawahi, M. Butnariu, L.S. Rotariu, H.A.R. Suleria, Y. Taheri, A.O. Docea, D. Calina, W.C. Cho, A. Literature-Based, Update on Benincasa hispida (Thunb.) Cogn.: traditional uses, nutraceutical, and phytopharmacological profiles, *Oxid. Med. Cell. Longev.* 2021 (2021), <https://doi.org/10.1155/2021/6349041>.
- [64] E.O.A. Airaodion, (PDF) Antidiabetic Effect of Ethanolic Extract of *Carica papaya* Leaves in Alloxan-Induced Diabetic Rats | Augustine I. Airaodion - Academia.edu, Academia. Edu., 2019.
- [65] N. Qazi, R. Alam Khan, G.H. Rizwani, Z. Feroz, Effect of *Carthamus tinctorius* (Safflower) on fasting blood glucose and insulin levels in alloxan induced diabetic rabbits, *Pak. J. Pharm. Sci.* 27 (2014) 377–380.
- [66] Z. Islam, M.R. Tahsin, A.U. Faisal, T.I. Tiithi, T.T. Nova, T.S. Nila, M.Z.H. Gorapi, F.A. Nadvi, T.N. Mridula, A.A. Choudhury, J.A. Chowdhury, S. Kabir, M. S. Amran, In vivo assessment of antidiabetic potential and mapping of pharmacological properties of ethanolic extract of leaves of *Coccinia grandis* in Alloxan-induced diabetic rats, *Asian J. Adv. Res. Rep.* (2019) 1–9, <https://doi.org/10.9734/AJARR/2019/V7I230169>.
- [67] V. Prachayasittikul, S. Prachayasittikul, S. Ruchirawat, V. Prachayasittikul, Coriander (*Coriandrum sativum*): a promising functional food toward the well-being, *Food Res. Int.* 105 (2018) 305–323, <https://doi.org/10.1016/j.foodres.2017.11.019>.
- [68] D. Mohamed, Antioxidant and Anti-diabetic Effects of Cumin Seeds Crude Ethanol Extract Some of the authors of this publication are also working on these related projects: food chemistry View project Impact of Safflower Petals and Moringa Leaves Extracts in Experiment, 2018, <https://doi.org/10.3923/jbs.2018.251.259>.
- [69] R. Papitha, K. Renu, C. Immanuel Selvaraj, V.G. Abilash, Anti-diabetic effect of fruits on different animal model system, bioorganic phase nat, *Food Overv.* (2018) 157–185, https://doi.org/10.1007/978-3-319-74210-6_9.
- [70] Chunlada Bualee, Anan Ounaron, Rattima Jeenapongsa, Antidiabetic and Long-term Effects of *Elaeocarpus grandiflorus*, Naresuan University Journal: Science and Technology (NUJST), Journal.Nu.Ac.Th., 2013.
- [71] N. Fatima, R.M. Hafizur, A. Hameed, S. Ahmed, M. Nisar, N. Kabir, Ellagic acid in *Embllica officinalis* exerts anti-diabetic activity through the action on β -cells of pancreas, *Eur. J. Nutr.* 56 (2015) 591–601, <https://doi.org/10.1007/S00394-015-1103-Y>.
- [72] N. Rajesh Baskar, N.B. Rajesh, M.S. Ganesh, W.S. Balaji, Modulation of diabetes and associated complications using ethanolic extract of green fruit of *Ficus racemosa* Linn. in alloxan induced rats, *Int. J. Bio Pharma Res.* 8 (2019) 2587–2592, <https://doi.org/10.21746/ijbpr.2019.8.5.6>.
- [73] S.F. Abouzeid, O.M. Ahmed, R.R. Ahmed, A. Mahmoud, E. Abdella, M.B. Ashour, Antihyperglycemic effect of crude extracts of some Egyptian plants and algae, *J. Med. Food* 17 (2014) 400–406, <https://doi.org/10.1089/JMF.2013.0068>.
- [74] Z. Hassan, M.F. Yam, M. Ahmad, A.P.M. Yusof, Antidiabetic properties and mechanism of action of *Gynura procumbens* water extract in streptozotocin-induced diabetic rats, *Molecules* 15 (2010) 9008–9023, <https://doi.org/10.3390/MOLECULES15129008>.
- [75] G.H.-I.J.R. Rosemary, Antidiabetic Effect of Roselle Calyces Extract (*Hibiscus sabdariffa* L.) in Streptozotocin Induced Mice | Health & Environmental Research Online (HERO), US EPA, Hero.Epa.Gov., 2014.
- [76] M.E. de Lima, A.Z.C. Colpo, H. Rosa, A.C.F. Salgueiro, M.P. da Silva, D. S. Noronha, A. Santamaria, V. Folmer, *Ilex paraguariensis* extracts reduce blood glucose, peripheral neuropathy and oxidative damage in male mice exposed to streptozotocin, *J. Funct. Foods* 44 (2018) 9–16, <https://doi.org/10.1016/J.JFF.2018.02.024>.
- [77] A.A. Asuk, n-Hexane leaf fraction of *Jatropha curcas* mitigates hyperglycemia and hepatic nitric oxide levels in diabetic rats, *IAA J. Org.* 7 (2021) 111–118.
- [78] H. Sebai, S. Selmi, K. Rtibi, A. Souli, N. Gharbi, M. Sakly, Lavender (*Lavandula stoechas* L.) essential oils attenuate hyperglycemia and protect against oxidative stress in alloxan-induced diabetic rats, *Lipids Health Dis.* 12 (2013), <https://doi.org/10.1186/1476-511X-12-189>.
- [79] B.G. Rao, A. Asha, N. Sai, D. Ramadevi, Pharmacognostic and in vitro anti diabetic activity on Aerial Parts of *Leucas aspera* (Willd), *Int. J. Pharmacogn. Phytochem. Res.* 10 (2018) 334–340, <https://doi.org/10.25258/phyto.10.10.3>.
- [80] D.H. Ngo, D.N. Ngo, T.T.N. Vo, T.S. Vo, Mechanism of action of *Mangifera indica* leaves for anti-diabetic activity, *Sci. Pharm.* 87 (2019) 13, <https://doi.org/10.3390/SCIPHARM87020013>.
- [81] M. Ja Chung, S.-Y. Cho, M. Javidul Haque Bhuiyan, K. Heon Kim, S.-J. Lee, Antidiabetic effects of lemon balm (*Melissa officinalis*) essential oil on glucose-and lipid-regulating enzymes in type 2 diabetic mice, *Camb. Org.* (2022), <https://doi.org/10.1017/S0007114510001765>.
- [82] G. Mahendran, L.U. Rahman, Ethnomedicinal, phytochemical and pharmacological updates on Peppermint (*Mentha × piperita* L.)—A review, *Phyther, Res* 34 (2020) 2088–2139, <https://doi.org/10.1002/PTR.6664>.
- [83] W. Wang, H. Xu, H. Chen, K. Tai, F. Liu, Y. Gao, In vitro antioxidant, anti-diabetic and antilipemic potentials of quercetagenin extracted from marigold (*Tagetes erecta* L.) inflorescence residues, *J. Food Sci. Technol.* 53 (2016) 2614–2624, <https://doi.org/10.1007/S13197-016-2228-6>.
- [84] M. van de Venter, S. Roux, L.C. Bungu, J. Louw, N.R. Crouch, O.M. Grace, V. Maharaj, P. Pillay, P. Sewnarain, N. Bhagwandin, P. Foll, Antidiabetic screening and scoring of 11 plants traditionally used in South Africa, *J. Ethnopharmacol.* 119 (2008) 81–86, <https://doi.org/10.1016/J.JEP.2008.05.031>.
- [85] B.E. van Wyk, A broad review of commercially important southern African medicinal plants, *J. Ethnopharmacol.* 119 (2008) 342–355, <https://doi.org/10.1016/J.JEP.2008.05.029>.

- [86] J.A.O. Ojewole, Antinociceptive, anti-inflammatory and antidiabetic properties of Hypoxis hemerocallidea Fisch. & C.A. Mey. (Hypoxidaceae) corm [‘African Potato’] aqueous extract in mice and rats, *J. Ethnopharmacol.* 103 (2006) 126–134, <https://doi.org/10.1016/J.JEP.2005.07.012>.
- [87] M.F. Khan, A.K. Rawat, S. Khatoun, M.K. Hussain, A. Mishra, D.S. Negi, In vitro and in vivo antidiabetic effect of extracts of Melia azedarach, Zanthoxylum alatum, and Tanacetum nubigenum, *Integr. Med. Res.* 7 (2018) 176, <https://doi.org/10.1016/J.IMR.2018.03.004>.
- [88] E.R.B. Shanmugasundaram, G. Rajeswari, K. Baskaran, B.R.R. Kumar, K. R. Shanmugasundaram, B.K. Ahmath, Use of *Gymnema sylvestris* leaf extract in the control of blood glucose in insulin-dependent diabetes mellitus, *J. Ethnopharmacol.* 30 (1990) 281–294, [https://doi.org/10.1016/0378-8741\(90\)90107-5](https://doi.org/10.1016/0378-8741(90)90107-5).
- [89] K. Tadera, Y. Minami, K. Takamatsu, T. Matsuoka, Inhibition of alpha-glucosidase and alpha-amylase by flavonoids, *J. Nutr. Sci. Vitaminol. (Tokyo)*. 52 (2006) 149–153, <https://doi.org/10.3177/JNSV.52.149>.
- [90] J. Le Song, X. Zhao, Q. Wang, T. Zhang, Protective effects of *Lagerstroemia speciosa* on 3-morpholinosydnonimine (SIN-1)-induced oxidative stress in HIT-T15 pancreatic β cells, *Mol. Med. Rep.* 7 (2013) 1607–1612, <https://doi.org/10.3892/mmr.2013.1396>.
- [91] R. Anandharajan, S. Jaiganesh, N.P. Shankernarayanan, R.A. Viswakarma, A. Balakrishnan, In vitro glucose uptake activity of *Aegles marmelos* and *Syzygium cumini* by activation of Glut-4, PI3 kinase and PPAR γ in L6 myotubes, *Phytomedicine* 13 (2006) 434–441, <https://doi.org/10.1016/J.PHYMED.2005.03.008>.
- [92] M.L. Barrett, J.K. Udani, A proprietary alpha-amylase inhibitor from white bean (*Phaseolus vulgaris*): a review of clinical studies on weight loss and glycemic control, *Nutr. J.* 10 (2011), <https://doi.org/10.1186/1475-2891-10-24>.
- [93] N. Uddin, M.R. Hasan, M.M. Hossain, A. Sarker, A.H.M. Nazmul Hasan, A.F. M. Mahmudul Islam, M.M.H. Chowdhury, M.S. Rana, In vitro α -amylase inhibitory activity and in vivo hypoglycemic effect of methanol extract of *Citrus macroptera* Montr. fruit, *Asian Pac. J. Trop. Biomed.* 4 (2014) 473–479, <https://doi.org/10.12980/APJTB.4.2014C1173>.
- [94] R. Subramanian, M.Z. Asmawi, A. Sadikun, A bitter plant with a sweet future? A comprehensive review of an oriental medicinal plant: *andrographis paniculata*, 2011 111, *Phytochem. Rev.* 11 (2011) 39–75, <https://doi.org/10.1007/S11101-011-9219-Z>.
- [95] A.M. Gray, P.R. Flatt, Insulin-secreting activity of the traditional antidiabetic plant *Viscum album* (mistletoe), *J. Endocrinol.* 160 (1999) 409–414, <https://doi.org/10.1677/JOE.0.1600409>.
- [96] J. Bindu, R.T. Narendhirakannan, Role of medicinal plants in the management of diabetes mellitus: a review, 3 *Biotech* 9 (2019), <https://doi.org/10.1007/S13205-018-1528-0>.
- [97] R. Kasole, H.D. Martin, J. Kimiywe, Traditional medicine and its role in the management of diabetes mellitus: “patients” and herbalists’ perspectives”, evidence-based complement, *Evid. Based Complement Altern. Med* 2019 (2019), <https://doi.org/10.1155/2019/2835691>.
- [98] M. Hasanpour, M. Iranshahy, M. Iranshahi, The application of metabolomics in investigating anti-diabetic activity of medicinal plants, *Biomed. Pharmacother.* 128 (2020), 110263, <https://doi.org/10.1016/J.BIOPHA.2020.110263>.
- [99] Z. Nazarian-Samani, R.D.E. Sewell, Z. Lorigooini, M. Rafieian-Kopaei, Medicinal plants with multiple effects on diabetes mellitus and its complications: a systematic review, *Curr. Diabetes Rep.* 18 (2018) 1–13, <https://doi.org/10.1007/S11892-018-1042-0/TABLES/2>.
- [100] C. Lankatillake, T. Huynh, D.A. Dias, Understanding glycaemic control and current approaches for screening antidiabetic natural products from evidence-based medicinal plants, *Plant Methods* 15 (2019), <https://doi.org/10.1186/S13007-019-0487-8>.
- [101] S. Guo, Insulin signaling, resistance, and metabolic syndrome: insights from mouse models into disease mechanisms, *J. Endocrinol.* 220 (2014) T1–T23, <https://doi.org/10.1530/JOE-13-0327>.
- [102] M.J. Robinson, M.H. Cobb, Mitogen-activated protein kinase pathways, *Curr. Opin. Cell Biol.* 9 (1997) 180–186, [https://doi.org/10.1016/S0955-0674\(97\)80061-0](https://doi.org/10.1016/S0955-0674(97)80061-0).
- [103] L.S. Harrington, G.M. Findlay, A. Gray, T. Tolkacheva, S. Wigfield, H. Rebholz, J. Barnett, N.R. Leslie, S. Cheng, P.R. Shepherd, I. Gout, C.P. Downes, R.F. Lamb, The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins, *J. Cell Biol.* 166 (2004) 213–223, <https://doi.org/10.1083/JCB.200403069>.
- [104] E.W. Kraegen, P.W. Clark, A.B. Jenkins, E.A. Daley, D.J. Chisholm, L.H. Storlien, Development of muscle insulin resistance after liver insulin resistance in high-fat-fed rats, *Diabetes* 40 (1991) 1397–1403, <https://doi.org/10.2337/DIAB.40.11.1397>.
- [105] A. Guilherme, J.V. Virbasius, V. Puri, M.P. Czech, Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes, *Nat. Rev. Mol. Cell Biol.* 9 (2008) 367–377, <https://doi.org/10.1038/nrm2391>.
- [106] J. Choi, K.J. Kim, E.J. Koh, B.Y. Lee, Gelidium elegans extract Ameliorates type 2 diabetes via regulation of MAPK and PI3K/Akt signaling, *Nutrients* 10 (2018) 51, <https://doi.org/10.3390/NU10010051>.
- [107] H. Choudhury, M. Pandey, C.K. Hua, C.S. Mun, J.K. Jing, L.Y. Ern, N. A. Ashraf, S.W. Kit, T.S. Yee, M.R. Pichika, B. Gorain, P. Kesharwani, An update on natural compounds in the remedy of diabetes mellitus: a systematic review, *J. Tradit. Complement. Med.* 8 (2018), <https://doi.org/10.1016/J.JTCME.2017.08.012>.
- [108] A. Ahangarpour, M. Mohammadian, M. Dianat, Antidiabetic effect of hydroalcoholic *urticadioica* leaf extract in male rats with fructose-induced insulin resistance, *Iran. J. Med. Sci.* 37 (2012) 181.
- [109] Y.S. Jaiswal, P.A. Tatke, S.Y. Gabhe, A.B. Vaidya, Antidiabetic activity of extracts of *Anacardium occidentale* Linn. leaves on n-streptozotocin diabetic rats, *J. Tradit. Complement. Med.* 7 (2017) 421–427, <https://doi.org/10.1016/J.JTCME.2016.11.007>.
- [110] K.A. Antu, M.P. Riya, A. Nair, A. Mishra, A.K. Srivastava, K.G. Raghu, *Symplocos cochinchinensis* enhances insulin sensitivity via the down regulation of lipogenesis and insulin resistance in high energy diet rat model, *J. Ethnopharmacol.* 193 (2016) 500–509, <https://doi.org/10.1016/J.JEP.2016.09.050>.
- [111] Y. Zhang, L. Yu, W. Cai, S. Fan, L. Feng, G. Ji, C. Huang, Protopanaxatriol, a novel PPAR γ antagonist from *Panax ginseng*, alleviates steatosis in mice, *Sci. Rep.* 4 (2014) 1–12, <https://doi.org/10.1038/srep07375>.
- [112] V. Ramachandran, R. Saravanan, Glucose uptake through translocation and activation of GLUT4 in PI3K/Akt signaling pathway by asiatic acid in diabetic rats, *Hum. Exp. Toxicol.* 34 (2015) 884–893, <https://doi.org/10.1177/0960327114561663>.
- [113] J.R. Wang, K.H. Ye, Y.Q. Lü, S.C. Wei, X.Q. Zhang, W.C. Ye, C.L. Ye, Effects of guavenoic acid on protection against oxidative damage in INS-1 Cells and its mechanisms, *Chin. Pharm. J.* 50 (2015) 233–238, <https://doi.org/10.11669/CPJ.2015.03.011>.
- [114] D. Arha, S. Pandeti, A. Mishra, S.P. Srivastava, A.K. Srivastava, T. Narender, A. K. Tamrakar, Deoxyandrographolide promotes glucose uptake through glucose transporter-4 translocation to plasma membrane in L6 myotubes and exerts antihyperglycemic effect in vivo, *Eur. J. Pharmacol.* 768 (2015) 207–216, <https://doi.org/10.1016/J.EJPHAR.2015.10.055>.
- [115] L. Jia, Y. Zhao, Current evaluation of the millennium phytomedicine- Ginseng (I): etymology, pharmacognosy, phytochemistry, market and regulations, *Curr. Med. Chem.* 16 (2009) 2475–2484, <https://doi.org/10.2174/092986709788682146>.
- [116] M.R. Tabandeh, S.A. Hosseini, M. Hosseini, Ginsenoside Rb1 exerts antidiabetic action on C2C12 muscle cells by leptin receptor signaling pathway, *J. Recept. Signal Transduct.* 37 (2017) 370–378, <https://doi.org/10.1080/10799893.2017.1286676>.
- [117] N. Nooron, A. Athipornchai, A. Suksamrarn, A. Chiabchalard, Mahanine enhances the glucose-lowering mechanisms in skeletal muscle and adipocyte cells, *Biochem. Biophys. Res. Commun.* 494 (2017) 101–106, <https://doi.org/10.1016/J.BBRC.2017.10.075>.
- [118] S.H. Kim, J.T. Hwang, H.S. Park, D.Y. Kwon, M.S. Kim, Capsaicin stimulates glucose uptake in C2C12 muscle cells via the reactive oxygen species (ROS)/AMPK/p38 MAPK pathway, *Biochem. Biophys. Res. Commun.* 439 (2013) 66–70, <https://doi.org/10.1016/J.BBRC.2013.08.027>.
- [119] G. Naresh, N. Jaiswal, P. Sukanya, A.K. Srivastava, A.K. Tamrakar, T. Narender, Glucose uptake stimulatory effect of 4-hydroxyxypipecolic acid by increased GLUT 4 translocation in skeletal muscle cells, *Bioorg. Med. Chem. Lett.* 22 (2012) 5648–5651, <https://doi.org/10.1016/J.BMCL.2012.06.101>.
- [120] C.M. Mangione, R.B. Gerzoff, D.F. Williamson, W.N. Steers, E.A. Kerr, A.F. Brown, B.E. Waitzfelder, D.G. Marrero, R.A. Dudley, C. Kim, W. Herman, T.J. Thompson, M.M. Safford, J.V. Selby, The association between quality of care and the intensity of diabetes disease management programs, *Ann. Intern. Med.* 145 (2006) 107–116, <https://doi.org/10.7326/0003-4819-145-2-200607180-00008>.
- [121] R.A. DeFronzo, Pharmacologic therapy for type 2 diabetes mellitus, *Ann. Intern. Med.* 131 (1999) 281–303, <https://doi.org/10.7326/0003-4819-131-4-199908170-00008>.
- [122] R.B. Goldberg, D.M. Kendall, M.A. Deeg, J.B. Buse, A.J. Zagar, J.A. Pinaire, M. H. Tan, M.A. Khan, A.T. Perez, S.J. Jacober, A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia, *Diabetes Care* 28 (2005) 1547–1554, <https://doi.org/10.2337/DIACARE.28.7.1547>.
- [123] P.D. Home, S.J. Pocock, H. Beck-Nielsen, R. Gomis, M. Hanefeld, N.P. Jones, M. Komajda, J.V.V. McMurray, Rosiglitazone evaluated for cardiovascular outcomes — an interim analysis, *New Engl. J. Med.* 357 (2007) 28–38, <https://doi.org/10.1056/NEJMOA073394>.
- [124] D.C. Simonson, E. Ferrannini, S. Bevilacqua, D. Smith, E. Barrett, R. Carlson, R. A. DeFronzo, Mechanism of improvement in glucose metabolism after chronic glyburide therapy, *Diabetes* 33 (1984) 838–845, <https://doi.org/10.2337/DIAB.33.9.838>.
- [125] J. Naveen, V. Baskaran, Antidiabetic plant-derived nutraceuticals: a critical review, *Eur. J. Nutr.* 57 (2018) 1275–1299, <https://doi.org/10.1007/S00394-017-1552-6>.
- [126] D.K. Patel, S.K. Prasad, R. Kumar, S. Hemalatha, An overview on antidiabetic medicinal plants having insulin mimetic property, *Asian Pac. J. Trop. Biomed.* 2 (2012) 320–330, [https://doi.org/10.1016/S2221-1691\(12\)60032-X](https://doi.org/10.1016/S2221-1691(12)60032-X).
- [127] J. Montonen, R. Järvinen, M. Heliövaara, A. Reunanen, A. Aromaa, P. Knekt, Food consumption and the incidence of type II diabetes mellitus, *Eur. J. Clin. Nutr.* 59 (2005) 441–448, <https://doi.org/10.1038/sj.ejcn.1602094>.
- [128] J. Montonen, P. Knekt, R. Järvinen, A. Aromaa, A. Reunanen, Whole-grain and fiber intake and the incidence of type 2 diabetes, *Am. J. Clin. Nutr.* 77 (2003) 622–629, <https://doi.org/10.1093/AJCN/77.3.622>.
- [129] J.S.L. De Munter, F.B. Hu, D. Spiegelman, M. Franz, R.M. Van Dam, Whole grain, bran, and germ intake and risk of type 2 diabetes: a prospective cohort study and systematic review, *PLoS Med.* 4 (2007) 1385–1395, <https://doi.org/10.1371/JOURNAL.PMED.0040261>.
- [130] A.G. Atanasov, B. Waltenberger, E.M. Pferschy-Wenzig, T. Linder, C. Wawrosch, P. Uhrin, V. Temml, L. Wang, S. Schwaiger, E.H. Heiss, J.M. Rollinger,

- D. Schuster, J.M. Breuss, V. Bochkov, M.D. Mihovilovic, B. Kopp, R. Bauer, V. M. Dirsch, H. Stuppner, Discovery and resupply of pharmacologically active plant-derived natural products: a review, *Biotechnol. Adv.* 33 (2015) 1582–1614, <https://doi.org/10.1016/j.biotechadv.2015.08.001>.
- [131] S. Gouthai, P. Ganesan, S.Y. Park, S. Fakurazi, D.K. Choi, P. Arulselvan, Natural phyto-bioactive compounds for the treatment of type 2 diabetes: inflammation as a target, *Nutrients* 8 (2016), <https://doi.org/10.3390/nu8080461>.
- [132] J.A. Ross, C.M. Kasum, DIETARY FLAVONOIDS: Bioavailability, Metabolic Effects, and Safety, <http://Dx.Doi.Org/10.1146/Annurev.Nutr.22.111401.144957>. 22 (2003) 19–34. <https://doi.org/10.1146/ANNUREV.NUTR.22.111401.144957>.
- [133] J.A.D.S. Emim, A.B. Oliveira, A.J. Lapa, Pharmacological evaluation of the anti-inflammatory activity of a Citrus Bioflavonoid, Hesperidin, and the isoflavonoids, dauricin and clausquinone, in rats and mice, *J. Pharm. Pharmacol.* 46 (1994) 118–122, <https://doi.org/10.1111/J.2042-7158.1994.TB03753.X>.
- [134] S. Akiyama, S.-I. Katsumata, K. Suzuki, Y. Ishimi, J. Wu, M. Uehara, Dietary hesperidin exerts hypoglycemic and hypolipidemic effects in streptozotocin-induced marginal type 1 diabetic rats, *Jstage. Jst. Go. Jp.* 46 (2010) 87–92, <https://doi.org/10.3164/jcjb.09-82>.
- [135] D. Jain, M.K. Bansal, R. Dalvi, A. Uppanlawar, R. Somani, Protective effect of diosmin against diabetic neuropathy in experimental rats, *J. Integr. Med.* 12 (2014) 35–41, <https://doi.org/10.1016/j.ji.2013.04.001>.
- [136] W. Lee, S.K. Ku, D. Lee, T. Lee, J.S. Bae, Emodin-6-O- β -D-glucoside inhibits high-glucose-induced vascular inflammation, *Inflammation* 37 (2014) 306–313, <https://doi.org/10.1007/s10753-013-9741-9>.
- [137] U.R. Moon, S.K. Sen, A. Mitra, Antioxidant capacities and acetylcholinesterase-inhibitory activity of *Hoppea fastigiata*, *J. Herbs Spices Med. Plants* 20 (2014) 115–123, <https://doi.org/10.1080/10496475.2013.840711>.
- [138] A. Rauf, T. Abu-Izneid, A.A. Khalil, M. Imran, Z.A. Shah, T. Bin Emran, S. Mitra, Z. Khan, F.A. Alhumaydhi, A.S.M. Aljohani, I. Khan, M.M. Rahman, P. Jeandet, T. A. Gondal, Berberine as a potential anticancer agent: a comprehensive review, *Molecules* 26 (2021) 7368, <https://doi.org/10.3390/MOLECULES26237368>.
- [139] M.M. Rahman, F. Islam, S. Afsana Mim, M.S. Khan, M.R. Islam, M.A. Haque, S. Mitra, T. Bin Emran, A. Rauf, Multifunctional therapeutic approach of nanomedicines against inflammation in cancer and aging, *J. Nanomater.* 2022 (2022) 1–19, <https://doi.org/10.1155/2022/4217529>.
- [140] M.M. Rahman, M.R. Islam, S. Shohag, M.T. Ahasan, N. Sarkar, H. Khan, A. M. Hasan, S. Cavalu, A. Rauf, Microbiome in cancer: role in carcinogenesis and impact in therapeutic strategies, *Biomed. Pharmacother.* 149 (2022), 112898, <https://doi.org/10.1016/j.biopha.2022.112898>.
- [141] R. Vinayagam, M. Jayachandran, B. Xu, Antidiabetic effects of simple phenolic acids: a comprehensive review, *Phytother. Res.* 30 (2016) 184–199, <https://doi.org/10.1002/ptr.5528>.
- [142] L.K. Chung, Y.H. Park, Y. Zheng, I.E. Brodsky, P. Hearing, D.L. Kastner, J.J. Chae, J.B. Bliska, The Yersinia virulence factor YopM hijacks host kinases to inhibit type III effector-triggered activation of the P-kinase signaling pathway, *Cell Host Microbe* 20 (2016) 296–306, <https://doi.org/10.1016/j.chom.2016.07.018>.
- [143] J.S. Noh, C.H. Park, T. Yokozawa, Treatment with oligonol, a low-molecular polyphenol derived from lychee fruit, attenuates diabetes-induced hepatic damage through regulation of oxidative stress and lipid metabolism, *Br. J. Nutr.* 106 (2011) 1013–1022, <https://doi.org/10.1017/S0007114511001322>.
- [144] M.I. Hernández-Alvarez, A. Díaz-Ramos, M. Berdasco, J. Cobb, E. Planet, D. Cooper, A. Pazderska, K. Wanic, D. O'Hanlon, A. Gomez, L.R. De La Ballina, M. Esteller, M. Palacin, D.J. O'Gorman, J.J. Nolan, A. Zorzano, Early-onset and classical forms of type 2 diabetes show impaired expression of genes involved in muscle branched-chain amino acids metabolism, *Sci. Rep.* 7 (2017) 1–12, <https://doi.org/10.1038/s41598-017-14120-6>.
- [145] M.M. Rahman, M.R. Islam, S. Shohag, M.E. Hossain, M.S. Rahaman, F. Islam, M. Ahmed, S. Mitra, M.U. Khandaker, A.M. Idris, K. Chidambaram, T. Bin Emran, S. Cavalu, The multifunctional role of herbal products in the management of diabetes and obesity: a comprehensive review, *Molecules* 27 (2022) 1713, <https://doi.org/10.3390/MOLECULES27051713>.
- [146] K. Mohammadian-Motlagh, M. Shamsi, N. Roozbahani, M. Karimi, R. Moradzadeh, Effect of theory-based education on promoting a healthy lifestyle in pre-diabetic women: RCT, *BMC Women's Heal.* 22 (2022) 1–9, <https://doi.org/10.1186/s12905-022-01608-1>.
- [147] A.G. Tabák, C. Herder, W. Rathmann, E.J. Brunner, M. Kivimäki, Prediabetes: a high-risk state for diabetes development, *Lancet* 379 (2012) 2279–2290, [https://doi.org/10.1016/S0140-6736\(12\)60283-9](https://doi.org/10.1016/S0140-6736(12)60283-9).
- [148] Y. Huang, X. Cai, W. Mai, M. Li, Y. Hu, Association between prediabetes and risk of cardiovascular disease and all cause mortality: systematic review and meta-analysis, *BMJ* 355 (2016), <https://doi.org/10.1136/bmj.i5953>.
- [149] K. Hristova, D. Pella, R.B. Singh, B.D. Dimitrov, H. Chaves, L. Juneja, T.K. Basu, L. Ozimek, A.K. Singh, S.S. Rastogi, T. Takahashi, D.W. Wilson, F. de Meester, S. Cheema, B. Milovanovic, H.S. Buttar, J. Fedacko, I. Petrov, S. Handjiev, A. Wilczynska, M.L. Garg, I. Shiu, R.K. Singh, Sofia declaration for prevention of cardiovascular diseases and type 2 diabetes mellitus: a scientific statement of the international college of cardiology and international college of nutrition, *World Heart J.* 6 (2014) 89–106, <https://doi.org/10.2/JQUERY.MIN.JS>.
- [150] M.A. Martínez-González, M. Bes-Rastrollo, L. Serra-Majem, D. Lairon, R. Estruch, A. Trichopoulos, Mediterranean food pattern and the primary prevention of chronic disease: recent developments, *Nutr. Rev.* 67 (2009) S111–S116, <https://doi.org/10.1111/J.1753-4887.2009.00172.X>.
- [151] M.A. Martínez-González, C. De La Fuente-Arillaga, J.M. Nunez-Cordoba, F. J. Basterra-Gortari, J.J. Beunza, Z. Vazquez, S. Benito, A. Tortosa, M. Bes-Rastrollo, Adherence to Mediterranean diet and risk of developing diabetes: prospective cohort study, *BMJ* 336 (2008) 1348–1351, <https://doi.org/10.1136/BMJ.395611.501007.BE>.
- [152] K. Esposito, R. Marfella, M. Ciotola, C. Di Palo, F. Giugliano, G. Giugliano, M. D'Armierto, F. D'Andrea, D. Giugliano, Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial, *JAMA* 292 (2004) 1440–1446, <https://doi.org/10.1001/JAMA.292.12.1440>.
- [153] K. Esposito, M.I. Maiorino, M. Ciotola, C. Di Palo, P. Scognamiglio, M. Gicchino, M. Petrizzo, F. Saccomanno, F. Beneduce, A. Ceriello, D. Giugliano, Effects of a Mediterranean-style diet on the need for antihyperglycemic drug therapy in patients with newly diagnosed type 2 diabetes: a randomized trial, *Ann. Intern. Med.* 151 (2009) 306–314, <https://doi.org/10.7326/0003-4819-151-5-200909010-00004>.
- [154] M.A. Bakhtavar, I. Afzal, Climate smart dry chain technology for safe storage of quinoa seeds, *Sci. Rep.* 10 (2020) 1–12, <https://doi.org/10.1038/s41598-020-69190-w>.
- [155] H.P. Burrieza, A.J. Rizzo, E. Moura Vale, V. Silveira, S. Maldonado, Shotgun proteomic analysis of quinoa seeds reveals novel lysine-rich seed storage globulins, *Food Chem.* 293 (2019) 299–306, <https://doi.org/10.1016/j.foodchem.2019.04.098>.
- [156] S. Navruz-Varli, N. Sanlier, Nutritional and health benefits of quinoa (*Chenopodium quinoa* Willd.), *J. Cereal Sci.* 69 (2016) 371–376, <https://doi.org/10.1016/j.jcsc.2016.05.004>.
- [157] P. Paško, P. Zagrodzki, H. Bartoń, J. Chłopicka, S. Gorinstein, Effect of Quinoa Seeds (*Chenopodium quinoa*) in diet on some biochemical parameters and essential elements in blood of high fructose-fed rats, *Plant Foods Hum. Nutr.* 65 (2010) 333–338, <https://doi.org/10.1007/s11130-010-0197-X/TABLES/2>.
- [158] B. de Falco, M. Amato, V. Lanzotti, Chia seeds products: an overview, *Phytochem. Rev.* 16 (2017) 745–760, <https://doi.org/10.1007/s11101-017-9511-7>.
- [159] A.O. Akinfenwa, A. Cheikhoussef, N. Cheikhoussef, A.A. Hussein, Cold pressed chia (*Salvia hispanica* L.) seed oil, *Cold Press. Oils* (2020) 181–190, <https://doi.org/10.1016/B978-0-12-818188-1.00015-3>.
- [160] G. Scapin, M.M. Schmidt, R.C. Prestes, C.S. da Rosa, Phenolics compounds, flavonoids and antioxidant activity of chia seed extracts (*Salvia hispanica*) obtained by different extraction conditions, *Int. Food Res. J.* 23 (2016) 2341–2346.
- [161] D.S. S, W.M. V, S.N. H, Cytoprotective effects of *Lepidium sativum* seed extract on liver and pancreas of HFD/STZ induced type 2 diabetic mice, *Int. J. Pharmacogn. Phytochem. Res.* 9 (2017) 502–507, <https://doi.org/10.25258/phyto.v9i2.8121>.
- [162] T. Jain, K. Grover, A. Comprehensive, Review on the nutritional and nutraceutical aspects of garden cress (*Lepidium sativum* Linn.), 2016 883, *Proc. Natl. Acad. Sci. India Sect. B Biol. Sci.* 88 (2016) 829–836, <https://doi.org/10.1007/S40011-016-0775-2>.
- [163] A.O. Ademiluyi, O.H. Oyeniran, T.O. Jimoh, G. Oboh, A.A. Boligon, Fluted pumpkin (*Telfairia occidentalis*) seed modulates some markers of erectile function in isolated rat's corpus cavernosum: influence of polyphenol and amino acid constituents, *J. Food Biochem.* 43 (2019), e13037, <https://doi.org/10.1111/JFBC.13037>.
- [164] A. Ghahremanloo, R. Hajipour, M. Hemmati, M. Moossavi, Z. Mohaqiq, The beneficial effects of pumpkin extract on atherogenic lipid, insulin resistance and oxidative stress status in high-fat diet-induced obese rats, *J. Complement. Integr. Med.* 15 (2018), <https://doi.org/10.1515/JCIM-2017-0051/MACHINEREDABLECITATION/RIS>.
- [165] D.K. Kushawaha, M. Yadav, S. Chatterji, A.K. Srivastava, G. Watal, Evidence based study of antidiabetic potential of *C. maxima* seeds – In vivo, *J. Tradit. Complement. Med.* 7 (2017) 466–470, <https://doi.org/10.1016/J.JTCME.2016.12.001>.
- [166] U.N. Rafiqi, I. Gul, M. Saifi, N. Nasrullah, J. Ahmad, P. Dash, M.Z. Abidin, Cloning, identification, and *in silico* analysis of terpene synthases involved in the competing pathways of artemisinin biosynthesis pathway in *Artemisia annua* L., *Pharmacogn. Mag.* 15 (2019) 38, <https://doi.org/10.4103/PM.PM.244.18>.
- [167] C. Zhou, Y. Qin, R. Chen, F. Gao, J. Zhang, F. Lu, Fenugreek attenuates obesity-induced inflammation and improves insulin resistance through downregulation of iRhom2/TACE, *Life Sci.* 258 (2020), 118222, <https://doi.org/10.1016/J.LFS.2020.118222>.
- [168] A.D. Kandhare, D. Bandyopadhyay, P.A. Thakurdesai, Low molecular weight galactomannans-based standardized fenugreek seed extract ameliorates high-fat diet-induced obesity in mice via modulation of FASN, IL-6, leptin, and TRIP-Br2, *RSC Adv.* 8 (2018) 32401–32416, <https://doi.org/10.1039/C8RA05204B>.
- [169] M.M. Rahman, M.R. Islam, S. Shohag, M.T. Ahasan, N. Sarkar, H. Khan, A. M. Hasan, S. Cavalu, A. Rauf, Microbiome in cancer: role in carcinogenesis and impact in therapeutic strategies, *Biomed. Pharmacother.* 149 (2022), 112898, <https://doi.org/10.1016/J.BIOPHA.2022.112898>.
- [170] M.M. Rahman, S. Bibi, M.S. Rahaman, F. Rahman, F. Islam, M.S. Khan, M. M. Hasan, A. Parvez, M.A. Hossain, S.K. Maeesa, M.R. Islam, A. Najda, H.S. Al-malky, H.R.H. Mohamed, H.I.M. AlGwaiz, A.A. Awaji, M.O. Germoush, O. A. Kensara, M.M. Abdel-Daim, M. Saeed, M.A. Kamal, Natural therapeutics and nutraceuticals for lung diseases: traditional significance, phytochemistry, and pharmacology, *Biomed. Pharmacother.* 150 (2022), 113041, <https://doi.org/10.1016/J.BIOPHA.2022.113041>.
- [171] M. Rahman, R. Islam, S. Shohag, E. Hossain, M. Shah, S. Khan Shuvo, H. Khan, A. R. Chowdhury, I.J. Bulbul, S. Hossain, S. Sultana, M. Ahmed, M.F. Akhtar, A. Saleem, H. Rahman, Multifaceted role of natural sources for COVID-19 pandemic as marine drugs, *Environ. Sci. Pollut. Res.* 2022 (2022) 1–24, <https://doi.org/10.1007/S11356-022-20328-5>.

- [172] M.M. Rahman, M.S. Rahaman, M.R. Islam, F. Rahman, F.M. Mithi, T. Alqahtani, M.A. Almikhlaifi, S.Q. Alghamdi, A.S. Alruwaili, M.S. Hossain, M. Ahmed, R. Das, T. Bin Emran, M.S. Uddin, Role of phenolic compounds in human disease: current knowledge and future prospects, *Molecules* 27 (2021) 233, <https://doi.org/10.3390/MOLECULES27010233>.
- [173] S. Zameer, A.K. Najmi, D. Vohora, M. Akhtar, A review on therapeutic potentials of *Trigonella foenugraecum* (fenugreek) and its chemical constituents in neurological disorders: Complementary roles to its hypolipidemic, hypoglycemic, and antioxidant potential, <https://doi.org/10.1080/1028415X.2017.1327200>, 21, 2017, 539–545, <https://doi.org/10.1080/1028415X.2017.1327200>.
- [174] M.M. Rahman, F. Islam, A. Parvez, M.A.K. Azad, G.M. Ashraf, M.F. Ullah, M. Ahmed, Citrus limon L. (lemon) seed extract shows neuro-modulatory activity in an in vivo thiopental-sodium sleep model by reducing the sleep onset and enhancing the sleep duration, *J. Integr. Neurosci.* 21 (2022), <https://doi.org/10.10380/J.JIN2101042/1757-448X-21-1-042/FIG1.JPG>.
- [175] T. Bhattacharya, G.A.B.E. Soares, H. Chopra, M.M. Rahman, Z. Hasan, S.S. Swain, S. Cavalu, Applications of phyto-nanotechnology for the treatment of neurodegenerative disorders, *Materials* 15 (2022) 804, <https://doi.org/10.3390/MA15030804>.
- [176] M. Mominur Rahman, F. Islam, M. Saidur Rahaman, N.A. Sultana, N.F. Fahim, M. Ahmed, Studies on the prevalence of HIV/AIDS in Bangladesh including other developing countries, *Adv. Tradit. Med.* 21 (2021) 1–12, <https://doi.org/10.1007/S13596-021-00610-6/FIGURES/2>.
- [177] M.M. Rahman, K.S. Ferdous, M. Ahmed, M.T. Islam, M.R. Khan, A. Perveen, G. M. Ashraf, M.S. Uddin, Hutchinson-Gilford progeria syndrome: an overview of the molecular mechanism, pathophysiology and therapeutic approach, *Curr. Gene Ther.* 21 (2021) 216–229, <https://doi.org/10.2174/1566523221666210303100805>.
- [178] M.M. Rahman, M.R. Islam, M.T. Islam, M. Harun-Or-rashid, M. Islam, S. Abdullah, M.B. Uddin, S. Das, M.S. Rahaman, M. Ahmed, F.A. Alhumaydhi, T. Bin Emran, A.A.R. Mohamed, M.R.I. Faruque, M.U. Khandaker, G. Mostafa-Hedeab, Stem cell transplantation therapy and neurological disorders: current status and future perspectives, *Biology* 11 (2022) 147, <https://doi.org/10.3390/BIOLOGY11010147>.
- [179] J. Weghuber, H. El-Askary, H.H. Salem, A.A. Motaal, Potential mechanisms involved in the protective effect of dicaffeoylquinic acids from *Artemisia annua* L. leaves against diabetes and its complications, *Molecules* 27 (2022) 857, <https://doi.org/10.3390/MOLECULES27030857>.
- [180] K. Bhagour, D. Arya, R.S. Gupta, A review: antihyperglycemic plant medicines in management of diabetes, *Acupunct. Relat. Ther.* 4 (2016) 7–16, <https://doi.org/10.1016/J.ARTHE.2016.11.001>.
- [181] T. Thirumalai, S.V. Therasa, E.K. Elumalai, E. David, Hypoglycemic effect of *Brassica juncea* (seeds) on streptozotocin induced diabetic male albino rat, *Asian Pac. J. Trop. Biomed.* 1 (2011) 323–325, [https://doi.org/10.1016/S2221-1691\(11\)60052-X](https://doi.org/10.1016/S2221-1691(11)60052-X).
- [182] J. Heshmati, N. Namazi, M.R. Memarzadeh, M. Taghizadeh, F. Kolaehod, *Nigella sativa* oil affects glucose metabolism and lipid concentrations in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial, *Food Res. Int.* 70 (2015) 87–93, <https://doi.org/10.1016/J.FOODRES.2015.01.030>.
- [183] T. Farkhondeh, S. Samarghandian, A. Borji, An overview on cardioprotective and anti-diabetic effects of thymoquinone, *Asian Pac. J. Trop. Med* 10 (2017) 849–854, <https://doi.org/10.1016/J.APJTM.2017.08.020>.
- [184] R. Daryabeygi-Khotbehsara, M. Golzarand, M.P. Ghaffari, K. Djafarian, *Nigella sativa* improves glucose homeostasis and serum lipids in type 2 diabetes: a systematic review and meta-analysis, *Complement. Ther. Med.* 35 (2017) 6–13, <https://doi.org/10.1016/J.CTJM.2017.08.016>.
- [185] A. Hamdan, R.H. Idrus, M.H. Mokhtar, Effects of *nigella sativa* on type-2 diabetes mellitus: a systematic review, *Int. J. Environ. Res. Public Heal.* 16 (2019) 4911, <https://doi.org/10.3390/IJERPH16244911>.
- [186] R. Mohebbati, A. Abbasnezhad, Effects of *Nigella sativa* on endothelial dysfunction in diabetes mellitus: a review, *J. Ethnopharmacol.* 252 (2020), 112585, <https://doi.org/10.1016/J.JEP.2020.112585>.
- [187] A. Kumar, K. Sundaram, Y. Teng, J. Mu, M.K. Sriwastva, L. Zhang, J.L. Hood, J. Yan, X. Zhang, J.W. Park, M.L. Merchant, H.G. Zhang, Ginger nanoparticles mediated induction of Foxa2 prevents high-fat diet-induced insulin resistance, *Theranostics* 12 (2022) 1388, <https://doi.org/10.7150/THNO.62514>.
- [188] H. Chopra, S. Bibi, I. Singh, M.M. Hasan, M.S. Khan, Q. Yousafi, A.A. Baig, M. M. Rahman, F. Islam, T. Bin Emran, S. Cavalu, Green metallic nanoparticles: biosynthesis to applications, *Front. Bioeng. Biotechnol.* 0 (2022) 548, <https://doi.org/10.3389/FBIOE.2022.874742>.
- [189] C. Quidse, J. Herrera-Bravo, Z. Javed, K. Khan, S. Raza, Z. Gulsunoglu-Konuskan, S.D. Daştan, O. Sytar, M. Martorell, J. Sharif-Rad, D. Calina, Therapeutic applications of curcumin in diabetes: a review and perspective, *Biomed. Res. Int.* 2022 (2022) 1–14, <https://doi.org/10.1155/2022/1375892>.
- [190] F. Islam, S. Bibi, A.F.K. Meem, M.M. Islam, M.S. Rahaman, S. Bepary, M. M. Rahman, M.M. Rahman, A. Elzaki, S. Kajoak, H. Osman, M. Elsamani, M. U. Khandaker, A.M. Idris, T. Bin Emran, Natural bioactive molecules: an alternative approach to the treatment and control of COVID-19, 2021, Vol. 22, Page 12638, *Int. J. Mol. Sci.* 22 (2021) 12638, <https://doi.org/10.3390/IJMS222312638>.
- [191] M.M. Rahman, M. Ahmed, M.T. Islam, M.R. Khan, S. Sultana, S.K. Maeesa, S. Hasan, M.A. Hossain, K.S. Ferdous, B. Mathew, A. Rauf, M.S. Uddin, Nanotechnology-based approaches and investigational therapeutics against COVID-19, *Curr. Pharm. Des.* 28 (2021), <https://doi.org/10.2174/1381612827666210701150315>.
- [192] F. Mollania, H. Sahabi, Investigating the ability of *Securigera securidaca* extract in biological synthesis of selenium nanoparticles, pancreatic α -amylase inhibition, antioxidant and phenolic capacity and in vivo studying the anti-diabetic effects of extract on pseudo-diabetic r, *Nanotechnol. Environ. Eng.* 7 (2021) 1–10, <https://doi.org/10.1007/S41204-021-00177-2>.
- [193] N.H. Salleh, I.N. Zulkpli, H. Mohd Yasin, F. Ja' Afar, N. Ahmad, W.A.N. Wan Ahmad, S.R. Ahmad, Systematic review of medicinal plants used for treatment of diabetes in human clinical trials: an ASEAN perspective, *Evid. -Based Complement. Altern. Med.* 2021 (2021), <https://doi.org/10.1155/2021/5570939>.
- [194] D. Ahmed, V. Kumar, A. Verma, P.S. Gupta, H. Kumar, V. Dhingra, V. Mishra, M. Sharma, Antidiabetic, renal/hepatic/pancreas/cardiac protective and antioxidant potential of methanol/dichloromethane extract of *Albizia Lebbeck* Benth. stem bark (ALEx) on streptozotocin induced diabetic rats, *BMC Complement. Altern. Med.* 14 (2014) 1–17, <https://doi.org/10.1186/1472-6882-14-243/FIGURES/12>.
- [195] P.A. Patel, M.P. Parikh, S. Johari, T.R. Gandhi, Antihyperglycemic activity of *Albizia lebbeck* bark extract in streptozotocin-nicotinamide induced type II diabetes mellitus rats, *Ayu* 36 (2015) 335, <https://doi.org/10.4103/0974-8520.182752>.
- [196] R. Kumar, B. Sharma, N.R. Tomar, P. Roy, A.K. Gupta, A. Kumar, In vivo evaluation of hypoglycemic Activity of Aloe spp. and identification of its mode of action on GLUT-4 gene expression in vitro, *Appl. Biochem. Biotechnol.* 164 (2011) 1246–1256, <https://doi.org/10.1007/S12010-011-9210-6>.
- [197] A. Noor, S. Gunasekaran, M.A. Vijayalakshmi, Improvement of insulin secretion and pancreatic β -cell function in streptozotocin-induced diabetic rats treated with Aloe vera extract, *Pharmacogn. Res* 9 (2017) S99, <https://doi.org/10.4103/PR.PR.75.17>.
- [198] P. Kamtchoung, S.D. Sokeng, P.F. Moundipa, P. Watcho, H.B. Jatsa, D. Lontsi, Protective role of *Anacardium occidentale* extract against streptozotocin-induced diabetes in rats, *J. Ethnopharmacol.* 62 (1998) 95–99, [https://doi.org/10.1016/S0378-8741\(97\)00159-1](https://doi.org/10.1016/S0378-8741(97)00159-1).
- [199] R. Dheer, P. Bhatnagar, A study of the antidiabetic activity of *Barleria prionitis*Linn, *Indian J. Pharmacol.* 42 (2010) 70, <https://doi.org/10.4103/0253-7613.64493>.
- [200] M. Ojezele, O. Abatan, Hypoglycaemic and coronary risk index lowering effects of *Bauhinia thonin* in alloxan induced diabetic rats, *Afr. Health Sci.* 11 (2011), <https://doi.org/10.4314/abs.v11i1.65001>.
- [201] A.M. Al-Attar, T.A. Zari, Influences of crude extract of tea leaves, *Camellia sinensis*, on streptozotocin diabetic male albino mice, *Saudi J. Biol. Sci.* 17 (2010) 295–301, <https://doi.org/10.1016/J.SJBS.2010.05.007>.
- [202] R. Gupta, M. Mathur, V.K. Bajaj, P. Katariya, S. Yadav, R. Kamal, R.S. Gupta, Evaluation of antidiabetic and antioxidant activity of *Moringa oleifera* in experimental diabetes, *J. Diabetes* 4 (2012) 164–171, <https://doi.org/10.1111/J.1753-0407.2011.00173.X>.
- [203] A. Villarruel-López, D.A. López-de la Mora, O.D. Vázquez-Paulino, A.G. Puebla-Mora, M.R. Torres-Vitela, L.A. Guerrero-Quiroz, K. Nuño, Effect of *Moringa oleifera* consumption on diabetic rats, *BMC Complement. Altern. Med.* 18 (2018) 1–10, <https://doi.org/10.1186/S12906-018-2180-2/FIGURES/4>.
- [204] A.N. Kesari, R.K. Gupta, G. Watal, Hypoglycemic effects of *Murraya koenigii* on normal and alloxan-diabetic rabbits, *J. Ethnopharmacol.* 97 (2005) 247–251, <https://doi.org/10.1016/J.JEP.2004.11.006>.
- [205] J. Pandey, R. Maurya, R. Raykhera, M.N. Srivastava, P.P. Yadav, A.K. Tamrakar, *Murraya koenigii* (L.) Spreng. ameliorates insulin resistance in dexamethasone-treated mice by enhancing peripheral insulin sensitivity, *J. Sci. Food Agric.* 94 (2014) 2282–2288, <https://doi.org/10.1002/JSSFA.6555>.
- [206] C. Luo, W. Zhang, C. Sheng, C. Zheng, J. Yao, Z. Miao, Chemical composition and antidiabetic activity of *Opuntia Milpa Alta* extracts, *Chem. Biodivers.* 7 (2010) 2869–2879, <https://doi.org/10.1002/CBDV.201000077>.
- [207] M. Vujicic, I. Nikolic, V.G. Kontogijanni, T. Saksida, P. Charisiadis, Z. Orescanin-Dusic, D. Blagojevic, S. Stosic-Grujicic, A.G. Tzakos, I. Stojanovic, Methanolic extract of *Origanum vulgare* ameliorates type 1 diabetes through antioxidant, anti-inflammatory and anti-apoptotic activity, *Br. J. Nutr.* 113 (2015) 770–782, <https://doi.org/10.1017/S0007114514004048>.
- [208] Q. Wang, X. Wu, F. Shi, Y. Liu, Comparison of antidiabetic effects of saponins and polysaccharides from *Momordica charantia* L. in STZ-induced type 2 diabetic mice, *Biomed. Pharmacother.* 109 (2019) 744–750, <https://doi.org/10.1016/J.BIOPHA.2018.09.098>.
- [209] M. Raish, A. Ahmad, B.L. Jan, K.M. Alkharfy, M.A. Ansari, K. Mohsin, F. al Jenooobi, A. Al-Mohizea, *Momordica charantia* polysaccharides mitigate the progression of STZ induced diabetic nephropathy in rats, *Int. J. Biol. Macromol.* 91 (2016) 394–399, <https://doi.org/10.1016/J.IJBIOMAC.2016.05.090>.
- [210] A.L.P. Pa Ap Pe Er R, S.L. Teoh, A. Abd Latiff, S. Das, J. Raja Muda Abdul Aziz, K. Lumpur, O OR RI IG GI IN NA Histological changes in the kidneys of experimental diabetic rats fed with *Momordica charantia* (bitter gourd) extract, *Rom. J. Morphol. Embryol.* 51 (2010) 91–95.
- [211] G.S. Kumar, A.K. Shetty, P.V. Salimath, Modulatory effect of bitter gourd (*Momordica charantia* LINN.) on alterations in kidney heparan sulfate in streptozotocin-induced diabetic rats, *J. Ethnopharmacol.* 115 (2008) 276–283, <https://doi.org/10.1016/J.JEP.2007.10.002>.
- [212] Z. Liu, J. Gong, W. Huang, F. Lu, H. Dong, The effect of *momordica charantia* in the treatment of diabetes mellitus: a review, *Evid. Based Complement. Altern. Med.* 2021 (2021), <https://doi.org/10.1155/2021/3796265>.
- [213] N.P.C. Fernandes, C.V. Lagishetty, V.S. Panda, S.R. Naik, An experimental evaluation of the antidiabetic and antilipidemic properties of a standardized

- Momordica charantia fruit extract, BMC Complement. Altern. Med. 7 (2007) 1–8, <https://doi.org/10.1186/1472-6882-7-29/TABLES/3>.
- [214] M.S. Hussain, N. Jahan, M.M. Or Rashid, M.S. Hossain, U. Chen, N. Rahman, Antihyperlipidemic screening and plasma uric acid reducing potential of Momordica charantia seeds on Swiss albino mice model, Heliyon 5 (2019), e01739, <https://doi.org/10.1016/J.HELIYON.2019.E01739>.
- [215] K. Azam, M.A. Rasheed, M.O. Omer, I. Altaf, A. Akhlaq, Anti-hyperlipidemic and anti-diabetic evaluation of ethanolic leaf extract of *Catharanthus roseus* alone and in combination therapy, Braz. J. Pharm. Sci. 58 (2022), <https://doi.org/10.1590/S2175-97902020000118672>.
- [216] K. Rasineni, R. Bellamkonda, S.R. Singareddy, S. Desireddy, Antihyperglycemic activity of *Catharanthus roseus* leaf powder in streptozotocin-induced diabetic rats, Pharmacogn. Res. 2 (2010) 195, <https://doi.org/10.4103/0974-8490.65523>.
- [217] S.C. Ohadoma, H.U. Michael, Effects of co-administration of methanol leaf extract of *Catharanthus roseus* on the hypoglycemic activity of metformin and glibenclamide in rats, Asian Pac. J. Trop. Med. 4 (2011) 475–477, [https://doi.org/10.1016/S1995-7645\(11\)60129-6](https://doi.org/10.1016/S1995-7645(11)60129-6).
- [218] G. Innocent Iyare, N. Terry Omorodion, T. Ogie Eramah, P. Uwadiogwu Achukwu, A. Grace Ogochukwu, The effects of *Anacardium occidentale* leaf extract on histology of selected organs of Wistar rats, Biol. Med. (2017), <https://doi.org/10.15406/mojbm.2017.02.00046>.
- [219] T.M. Archana, K. Soumya, J. James, S. Sudhakaran, Root extracts of *Anacardium occidentale* reduce hyperglycemia and oxidative stress in vitro, Clin. Phytosci. 7 (2021) 1–9, <https://doi.org/10.1186/S40816-021-00293-1>.
- [220] A. Kumar, R. Ilavarasan, T. Jayachandran, M. Deecaraman, P. Aravindan, N. Padmanabhan, M.R.V. Krishan, Anti-diabetic activity of *Syzygium cumini* and its isolated compound against streptozotocin-induced diabetic rats, J. Med. Plants Res. 2 (2008) 246–249.
- [221] S. Parmaki, I. Vyrides, M.I. Vasquez, V. Hartman, I. Zacharia, I. Hadjiadamou, C. B.M. Barbeitos, F.C. Ferreira, C.A.M. Afonso, C. Drouza, M. Koutinas, Bioconversion of alkaloids to high-value chemicals: comparative analysis of newly isolated lupanine degrading strains, Chemosphere 193 (2018) 50–59, <https://doi.org/10.1016/J.CHEMOSPHERE.2017.10.165>.
- [222] F. Cabello-Hurtado, J. Keller, J. Ley, R. Sanchez-Lucas, J.V. Jorrín-Novo, A. Ainouche, Proteomics for exploiting diversity of lupin seed storage proteins and their use as nutraceuticals for health and welfare, J. Proteom. 143 (2016) 57–68, <https://doi.org/10.1016/J.JPROT.2016.03.026>.
- [223] B.A. Yildirim, A. Ertekin, S. Kordali, S. Yildirim, Antidiabetic and antioxidant effects of *Lupinus albus* L. seed roasting ethanol extract in streptozotocin diabetic rats, World J. Adv. Res. Rev. 2020 (2020) 2581–9615, <https://doi.org/10.30574/wjarr>.
- [224] S. Pascoe-González, M.G. Ramos-Zavala, M.A. Buenrostro Ahued, S.O. Hernández-González, E.G. Cardona-Muñoz, L. García-Benavides, F. Grover-Páez, Administration of Herbarium mixture (*Guazuma ulmifolia*/*Tecoma stans*) on metabolic profile in type 2 diabetes mellitus patients: a randomized, double-blind (Https://Home.Liebertpub.Com/Jmf), Place. Control. Trial 24 (2021) 527–532, <https://doi.org/10.1089/JMF.2020.0082>.
- [225] A. Savych, O. Bilyk, V. Vaschuk, I. Humeniuk, Analysis of inulin and fructans in *Taraxacum officinale* L. roots as the main inulin-containing component of antidiabetic herbal mixture, Pharmacia 68 (2021) 527–532, <https://doi.org/10.3897/PHARMACIA.68.E66266>.
- [226] S.G. Karkute, T.K. Koley, B.K. Yengkhom, A. Tripathi, S. Srivastava, A. Maurya, B. Singh, Anti-diabetic phenolic compounds of black carrot (*Daucus carota* Subspecies sativus var. atrorubens Alef.) inhibit enzymes of glucose metabolism: an in silico and in vitro validation, Med. Chem. 14 (2018) 641–649, <https://doi.org/10.2174/1573406414666180301092819>.